Rewrite without altering any single word of following questions - 1. A

Rewrite without altering any single word of following questions - ## 1. Antitussives and Expectorants These agents manage respiratory conditions by either suppressing the cough reflex or facilitating mucus clearance. ## Classification and Mechanisms * Central Antitussives (Opioids): Codeine, dextromethorphan. They suppress the cough center in the medulla oblongata. * Peripheral Antitussives: Prenoxdiazine, levodropropizine. They reduce the sensitivity of respiratory tract stretch receptors. * Secretomotor Expectorants: Ammonium chloride, potassium iodide. They irritate the gastric mucosa to reflexively increase bronchial secretions. * Mucolytics: N-acetylcysteine, ambroxol, bromhexine. N-acetylcysteine breaks disulfide bonds in mucoproteins to liquefy mucus. Ambroxol stimulates surfactant production. ## Indications * Antitussives: Dry, non-productive, exhausting coughs (e.g., post-viral cough, lung cancer). * Expectorants/Mucolytics: Productive coughs with thick, viscous sputum (e.g., bronchitis, COPD, cystic fibrosis). ## Side Effects * Opioid Antitussives: Sedation, constipation, respiratory depression, addiction potential. * Expectorants/Mucolytics: Gastrointestinal irritation, nausea, bronchospasm (especially with inhaled mucolytics in asthmatics). ------------------------------ ## 2. Bronchodilators Bronchodilators relax bronchial smooth muscle to reverse airway obstruction. ## Classification and Mechanisms * β₂-Adrenergic Agonists: * SABA (Short-Acting): Salbutamol, albuterol. * LABA (Long-Acting): Salmeterol, formoterol. * Mechanism: Stimulate β₂-receptors → activate adenylyl cyclase → increase cAMP → smooth muscle relaxation. * Anticholinergics (Muscarinic Antagonists): * SAMA: Ipratropium bromide. * LAMA: Tiotropium bromide. * Mechanism: Block M₃ muscarinic receptors → inhibit vagal bronchoconstriction and mucus secretion. * Methylxanthines: Theophylline, aminophylline. * Mechanism: Inhibit phosphodiesterase (PDE), increasing cAMP. They also block adenosine receptors. ## Treatment of Asthma and Broncho-Obstructive Syndromes * Acute Asthma Exacerbation: Fast-acting SABAs (salbutamol) serve as first-line rescue therapy, often combined with SAMAs (ipratropium). * Chronic Asthma Maintenance: Formoterol or salmeterol are used, always paired with an inhaled corticosteroid (ICS) to manage inflammation. * COPD Management: LAMAs and LABAs are the foundational maintenance therapies to minimize air trapping. ## Side Effects * β₂-Agonists: Skeletal muscle tremors, tachycardia, palpitations, hypokalemia. * Anticholinergics: Dry mouth, urinary retention, blurred vision, constipation. * Methylxanthines: Narrow therapeutic window. Causes insomnia, severe arrhythmias, seizures, and vomiting. ------------------------------ ## 3. Cardiac Glycosides Cardiac glycosides (e.g., Digoxin) are positive inotropic and negative chronotropic agents derived from Digitalis plants. ## Mechanisms of Action * Inhibition of Na⁺/K⁺-ATPase Pump: Digoxin binds to this membrane pump, increasing intracellular Na⁺. This slows the Na⁺/Ca²⁺-exchanger, raising intracellular Ca²⁺ accumulation in the sarcoplasmic reticulum, which enhances cardiac contractility (Positive Inotropy). * Heart Rate and Conduction: Increases vagal (parasympathetic) tone. This slows the sinoatrial (SA) node firing rate (Negative Chronotropy) and prolongs conduction through the atrioventricular (AV) node (Negative Dromotropy). * Hemodynamics: Increases cardiac output in failing hearts, lowers left ventricular end-diastolic pressure, and reduces systemic vascular resistance via baroreceptor restoration. * Renal Function: Increased cardiac output improves renal perfusion. This promotes diuresis and reduces renin-angiotensin-aldosterone system (RAAS) activation. ## Indications * Chronic heart failure with reduced ejection fraction (HFrEF) symptomatic despite optimal therapy. * Ventricular rate control in patients with atrial fibrillation or atrial flutter. ------------------------------ ## 4. Glycoside Intoxication (Digitalis Toxicity) Digoxin has a very narrow therapeutic index (0.5 - 2.0 ng/mL), making toxicity a frequent clinical challenge. ## Pathogenesis and Contributing Factors Toxicity is driven by excessive intracellular Ca²⁺ overload and severe Na⁺/K⁺-ATPase inhibition. Hypokalemia worsens toxicity because potassium competes with digoxin for the pump binding site. Hypomagnesemia and hypercalcemia also increase sensitivity. ## Stages and Symptoms * Gastrointestinal (Early): Anorexia, nausea, vomiting, abdominal pain. * Neurological/Visual: Fatigue, confusion, delirium, xanthopsia (yellow-green halos around lights). * Cardiac (Late/Severe): Increased automaticity combined with decreased AV conduction. Leads to premature ventricular contractions (PVCs), bidirectional ventricular tachycardia, or high-degree AV blocks. ## Management 1. Discontinuation: Stop digoxin and any potassium-wasting diuretics immediately. 2. Electrolyte Correction: Administer potassium if hypokalemia is present (maintain normal-to-high levels, provided there is no high-degree AV block). 3. Antiarrhythmics: Phenytoin or lidocaine are preferred for digitalis-induced ventricular arrhythmias. Avoid Class IA agents and calcium channel blockers. 4. Specific Antidote: Administer Digoxin-specific antibody fragments (DigiFab) for life-threatening arrhythmias, severe hyperkalemia, or massive overdoses. [1] ------------------------------ ## 5. Antiarrhythmic Agents Class I Class I antiarrhythmics block voltage-gated sodium channels (Na⁺ channels) during Phase 0 of the cardiac action potential. ## Classification and Mechanisms * Class IA (Moderate block; prolongs repolarization): Quinidine, procainamide, disopyramide. They block Na⁺ channels and block K⁺ channels, prolonging the action potential duration (APD) and QT interval. * Class IB (Weak block; shortens repolarization): Lidocaine, mexiletine. They bind preferentially to inactivated Na⁺ channels in ischemic tissues, shortening APD. * Class IC (Strong block; no effect on repolarization): Flecainide, propafenone. They markedly slow Phase 0 depolarization and significantly decrease conduction velocity with minimal effect on APD. Phase 0 Depolarization Slope: Normal Action Potential: / Class IB Alteration: / (Mild decrease) Class IA Alteration: / (Moderate decrease) Class IC Alteration: / (Severe flattening) ## Indications * Class IA: Atrial fibrillation rhythm control, ventricular tachycardia. * Class IB: Acute ventricular arrhythmias, particularly post-myocardial infarction or digitalis-induced. * Class IC: Supraventricular tachycardias (SVT), atrial fibrillation in patients without structural heart disease. ## Side Effects * Class IA: Torsades de pointes (due to prolonged QT), drug-induced lupus (procainamide), cinchonism (quinidine). * Class IB: CNS toxicity (confusion, paresthesias, seizures, slurred speech). * Class IC: Highly proarrhythmic (especially post-MI, as demonstrated in the CAST trial), metallic taste (propafenone). ------------------------------ ## 6. Calcium Channel Blockers (CCBs) CCBs inhibit the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac cells. ## Classification and Mechanisms * Dihydropyridines (Vascular-selective): Amlodipine, nifedipine, felodipine. * Mechanism: Bind to vascular smooth muscle L-type channels → cause marked peripheral vasodilation with minimal direct cardiac effects. * Non-Dihydropyridines (Cardio-selective): Verapamil (phenylalkylamine), diltiazem (benzothiazepine). * Mechanism: Bind to L-type channels in the myocardium, SA node, and AV node → decrease contractility (negative inotropy), heart rate (negative chronotropy), and conduction velocity (negative dromotropy). ## Indications * Dihydropyridines: Hypertension, angina pectoris, Raynaud's phenomenon. * Non-Dihydropyridines: Rate control in atrial fibrillation/flutter, supraventricular tachycardia (SVT) prophylaxis, angina pectoris. ## Side Effects * Dihydropyridines: Peripheral edema, reflex tachycardia, flushing, headaches. * Non-Dihydropyridines: Bradycardia, AV block, constipation (especially verapamil), exacerbation of HFrEF. ------------------------------ ## 7. Nitrates Nitrates are prodrugs that act as potent vasodilators, primarily affecting the venous system. ## Mechanisms and Features of Action * Biotransformation: Nitrates (e.g., nitroglycerin, isosorbide dinitrate) are denitrated to release Nitric Oxide (NO). * Intracellular Pathway: NO stimulates soluble guanylyl cyclase → increases intracellular cyclic GMP (cGMP) → activates protein kinase G → dephosphorylation of myosin light chains → smooth muscle relaxation. * Hemodynamic Effects: At therapeutic doses, nitrates cause venous dilation over arterial dilation. This increases venous capacitance, reduces venous return (preload), and lowers left ventricular wall tension, which decreases myocardial oxygen demand. Higher doses cause arterial dilation, reducing afterload. * Nitrate Tolerance: Continuous exposure leads to a depletion of sulfhydryl groups or increased free radical production, neutralizing the drug's effect. A nitrate-free interval of 10-12 hours daily is mandatory to prevent this. ## Use * Acute relief and prophylaxis of angina pectoris. * Acute decompensated heart failure (to rapidly reduce preload). * Hypertensive emergencies (intravenous nitroglycerin). ## Side Effects * Throbbing headache (due to meningeal artery dilation). * Reflex tachycardia (due to baroreceptor response to blood pressure drops). * Orthostatic hypotension, dizziness, facial flushing. * Contraindication: Absolute contraindication with phosphodiesterase-5 (PDE-5) inhibitors like sildenafil, which can lead to life-threatening hypotension. ------------------------------ ## 8. Lipid-Lowering Agents Lipid-lowering agents alter plasma lipoprotein metabolism to decrease atherosclerotic plaque formation. ## Classification and Principles of Action * HMG-CoA Reductase Inhibitors (Statins): Inhibit cholesterol synthesis. * Cholesterol Absorption Inhibitors: Ezetimibe. Blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestine to lower dietary cholesterol uptake. * PCSK9 Inhibitors: Alirocumab, evolocumab. Monoclonal antibodies that prevent LDL receptor degradation, leaving more receptors available to clear LDL from the blood. * Fibric Acid Derivatives (Fibrates): Fenofibrate, gemfibrozil. Activate PPAR-alpha to upregulate lipoprotein lipase, primarily clearing triglycerides. * Bile Acid Sequestrants: Cholestyramine, colesevelam. Bind bile acids in the gut, forcing the liver to consume plasma cholesterol to synthesize new bile. ## Statins: Mechanism, Indications, and Side Effects * Mechanism: Competitively inhibit HMG-CoA reductase. This halts the conversion of HMG-CoA to mevalonate (the rate-limiting step in cholesterol synthesis). Decreased intracellular cholesterol triggers the liver to upregulate surface LDL receptors, removing circulating LDL from the blood. * Indications: Hypercholesterolemia, primary and secondary prevention of cardiovascular events (e.g., myocardial infarction, stroke). [1] * Side Effects: Myalgia, myopathy, rare rhabdomyolysis (risk increases when combined with fibrates or CYP3A4 inhibitors), elevated liver transaminases (hepatotoxicity), and a slight increase in blood glucose levels. Statins are strictly contraindicated in pregnancy. ------------------------------ ## 9. Diuretics: Classification and General Mechanisms Diuretics increase urine volume by altering the transport of sodium and water across the nephron, thereby lowering blood volume and pressure. [2] [NEPHRON SITE MAP] Cortex (PCT) --> (DCT) ---------+ | | v v Medulla (Loop of Henle) -----> (Collecting Duct) ## Classification by Site of Nephron Action 1. Proximal Convoluted Tubule (PCT): Carbonic anhydrase inhibitors, Osmotic diuretics. 2. Thick Ascending Limb of the Loop of Henle: Loop diuretics. 3. Distal Convoluted Tubule (DCT): Thiazide and thiazide-like diuretics. 4. Cortical Collecting Tubule: Potassium-sparing diuretics. ------------------------------ ## 10. Carbonic Anhydrase Inhibitors and Osmotic Diuretics These agents work early in the nephron but are rarely used for systemic edema due to weak diuretic efficacy. ## Carbonic Anhydrase Inhibitors (e.g., Acetazolamide) * Mechanism: Inhibits carbonic anhydrase in the PCT lumen and cytoplasm. This halts the conversion of H₂CO₃ into CO₂ and H₂O, preventing NaHCO₃ reabsorption and forcing sodium and bicarbonate to remain in the urine. * Features: Causes significant alkaline diuresis and metabolic acidosis. * Uses: Glaucoma (reduces aqueous humor production), acute mountain sickness, urinary alkalinization. * Side Effects: Hyperchloremic metabolic acidosis, hypokalemia, kidney stones (calcium phosphate precipitates in alkaline urine), sulfonamide allergy hypersensitivity. [3] ## Osmotic Diuretics (e.g., Mannitol) [4] * Mechanism: Mannitol is a non-absorbable solute filtered freely at the glomerulus. It acts along the entire tubule (mainly the PCT and descending loop) to create an osmotic gradient that holds water in the lumen. * Features: It extracts water from intracellular compartments into the bloodstream before it is filtered, expanding extracellular fluid volume initially. * Uses: Reduction of intracranial pressure (cerebral edema), reduction of intraocular pressure. * Side Effects: Transient extracellular volume expansion (can precipitate acute pulmonary edema or heart failure), dehydration, hypernatremia. ------------------------------ ## 11. Loop Diuretics, Thiazides, and Thiazide-Like Diuretics These are the primary drug classes used to manage volume overload and hypertension. ## Loop Diuretics (e.g., Furosemide, Bumetanide, Torsemide) * Mechanism: Reversibly inhibit the Na⁺/K⁺/2Cl⁻ cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. By blocking this transporter, they halt the reabsorption of 25% of the filtered sodium load. They also disrupt the lumen-positive potential, preventing Ca²⁺ and Mg²⁺ reabsorption. * Features: High-ceiling diuretics with potent action. They remain effective even in patients with low glomerular filtration rates (GFR). * Indications: Acute pulmonary edema, chronic heart failure edema, hepatic cirrhosis edema, renal failure edema, severe hypercalcemia. * Side Effects: Hypokalemia, metabolic alkalosis, hypomagnesemia, hypocalcemia, hyperuricemia (gout flare), ototoxicity (hearing loss), sulfonamide allergy. ## Thiazide and Thiazide-Like Diuretics (e.g., Hydrochlorothiazide, Chlorthalidone, Indapamide) * Mechanism: Inhibit the Na⁺/Cl⁻ cotransporter (NCC) in the early distal convoluted tubule, blocking 5-10% of sodium reabsorption. This increases distal delivery of sodium, which enhances Ca²⁺ reabsorption in the DCT via the basolateral Na⁺/Ca²⁺ exchanger. * Features: They lose efficacy when GFR drops below 30 mL/min (except indapamide and metolazone). * Indications: Essential hypertension (first-line), mild heart failure edema, nephrogenic diabetes insipidus, calcium nephrolithiasis (hypercalciuria prevention). * Side Effects: Hypokalemia, metabolic alkalosis, hyponatremia, hypercalcemia, hyperuricemia, hyperglycemia, hyperlipidemia.

Here is the rewritten version with identical wording, reformatted for clarity:

1. Antitussives and Expectorants

These agents manage respiratory conditions by either suppressing the cough reflex or facilitating mucus clearance.

Classification and Mechanisms

Central Antitussives (Opioids): Codeine, dextromethorphan. They suppress the cough center in the medulla oblongata.

Peripheral Antitussives: Prenoxdiazine, levodropropizine. They reduce the sensitivity of respiratory tract stretch receptors.

Secretomotor Expectorants: Ammonium chloride, potassium iodide. They irritate the gastric mucosa to reflexively increase bronchial secretions.

Mucolytics: N-acetylcysteine, ambroxol, bromhexine. N-acetylcysteine breaks disulfide bonds in mucoproteins to liquefy mucus. Ambroxol stimulates surfactant production.

Indications

Antitussives: Dry, non-productive, exhausting coughs (e.g., post-viral cough, lung cancer).

Expectorants/Mucolytics: Productive coughs with thick, viscous sputum (e.g., bronchitis, COPD, cystic fibrosis).

Side Effects

Opioid Antitussives: Sedation, constipation, respiratory depression, addiction potential.

Expectorants/Mucolytics: Gastrointestinal irritation, nausea, bronchospasm (especially with inhaled mucolytics in asthmatics).

2. Bronchodilators

Bronchodilators relax bronchial smooth muscle to reverse airway obstruction.

Classification and Mechanisms

β₂-Adrenergic Agonists:

SABA (Short-Acting): Salbutamol, albuterol.
LABA (Long-Acting): Salmeterol, formoterol.
Mechanism: Stimulate β₂-receptors → activate adenylyl cyclase → increase cAMP → smooth muscle relaxation.

Anticholinergics (Muscarinic Antagonists):

SAMA: Ipratropium bromide.
LAMA: Tiotropium bromide.
Mechanism: Block M₃ muscarinic receptors → inhibit vagal bronchoconstriction and mucus secretion.

Methylxanthines: Theophylline, aminophylline.

Mechanism: Inhibit phosphodiesterase (PDE), increasing cAMP. They also block adenosine receptors.

Treatment of Asthma and Broncho-Obstructive Syndromes

Acute Asthma Exacerbation: Fast-acting SABAs (salbutamol) serve as first-line rescue therapy, often combined with SAMAs (ipratropium).

Chronic Asthma Maintenance: Formoterol or salmeterol are used, always paired with an inhaled corticosteroid (ICS) to manage inflammation.

COPD Management: LAMAs and LABAs are the foundational maintenance therapies to minimize air trapping.

Side Effects

β₂-Agonists: Skeletal muscle tremors, tachycardia, palpitations, hypokalemia.

Anticholinergics: Dry mouth, urinary retention, blurred vision, constipation.

Methylxanthines: Narrow therapeutic window. Causes insomnia, severe arrhythmias, seizures, and vomiting.

3. Cardiac Glycosides

Cardiac glycosides (e.g., Digoxin) are positive inotropic and negative chronotropic agents derived from Digitalis plants.

Mechanisms of Action

Inhibition of Na⁺/K⁺-ATPase Pump: Digoxin binds to this membrane pump, increasing intracellular Na⁺. This slows the Na⁺/Ca²⁺-exchanger, raising intracellular Ca²⁺ accumulation in the sarcoplasmic reticulum, which enhances cardiac contractility (Positive Inotropy).

Heart Rate and Conduction: Increases vagal (parasympathetic) tone. This slows the sinoatrial (SA) node firing rate (Negative Chronotropy) and prolongs conduction through the atrioventricular (AV) node (Negative Dromotropy).

Hemodynamics: Increases cardiac output in failing hearts, lowers left ventricular end-diastolic pressure, and reduces systemic vascular resistance via baroreceptor restoration.

Renal Function: Increased cardiac output improves renal perfusion. This promotes diuresis and reduces renin-angiotensin-aldosterone system (RAAS) activation.

Indications

Chronic heart failure with reduced ejection fraction (HFrEF) symptomatic despite optimal therapy.
Ventricular rate control in patients with atrial fibrillation or atrial flutter.

4. Glycoside Intoxication (Digitalis Toxicity)

Digoxin has a very narrow therapeutic index (0.5 - 2.0 ng/mL), making toxicity a frequent clinical challenge.

Pathogenesis and Contributing Factors

Toxicity is driven by excessive intracellular Ca²⁺ overload and severe Na⁺/K⁺-ATPase inhibition. Hypokalemia worsens toxicity because potassium competes with digoxin for the pump binding site. Hypomagnesemia and hypercalcemia also increase sensitivity.

Stages and Symptoms

Gastrointestinal (Early): Anorexia, nausea, vomiting, abdominal pain.

Neurological/Visual: Fatigue, confusion, delirium, xanthopsia (yellow-green halos around lights).

Cardiac (Late/Severe): Increased automaticity combined with decreased AV conduction. Leads to premature ventricular contractions (PVCs), bidirectional ventricular tachycardia, or high-degree AV blocks.

Management

Discontinuation: Stop digoxin and any potassium-wasting diuretics immediately.
Electrolyte Correction: Administer potassium if hypokalemia is present (maintain normal-to-high levels, provided there is no high-degree AV block).
Antiarrhythmics: Phenytoin or lidocaine are preferred for digitalis-induced ventricular arrhythmias. Avoid Class IA agents and calcium channel blockers.
Specific Antidote: Administer Digoxin-specific antibody fragments (DigiFab) for life-threatening arrhythmias, severe hyperkalemia, or massive overdoses. [1]

5. Antiarrhythmic Agents - Class I

Class I antiarrhythmics block voltage-gated sodium channels (Na⁺ channels) during Phase 0 of the cardiac action potential.

Classification and Mechanisms

Class IA (Moderate block; prolongs repolarization): Quinidine, procainamide, disopyramide. They block Na⁺ channels and block K⁺ channels, prolonging the action potential duration (APD) and QT interval.

Class IB (Weak block; shortens repolarization): Lidocaine, mexiletine. They bind preferentially to inactivated Na⁺ channels in ischemic tissues, shortening APD.

Class IC (Strong block; no effect on repolarization): Flecainide, propafenone. They markedly slow Phase 0 depolarization and significantly decrease conduction velocity with minimal effect on APD.

Action Potential	Phase 0 Depolarization Slope
Normal	/
Class IB Alteration	/ (Mild decrease)
Class IA Alteration	/ (Moderate decrease)
Class IC Alteration	/ (Severe flattening)

Indications

Class IA: Atrial fibrillation rhythm control, ventricular tachycardia.

Class IB: Acute ventricular arrhythmias, particularly post-myocardial infarction or digitalis-induced.

Class IC: Supraventricular tachycardias (SVT), atrial fibrillation in patients without structural heart disease.

Side Effects

Class IA: Torsades de pointes (due to prolonged QT), drug-induced lupus (procainamide), cinchonism (quinidine).

Class IB: CNS toxicity (confusion, paresthesias, seizures, slurred speech).

Class IC: Highly proarrhythmic (especially post-MI, as demonstrated in the CAST trial), metallic taste (propafenone).

6. Calcium Channel Blockers (CCBs)

CCBs inhibit the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac cells.

Classification and Mechanisms

Dihydropyridines (Vascular-selective): Amlodipine, nifedipine, felodipine.

Mechanism: Bind to vascular smooth muscle L-type channels → cause marked peripheral vasodilation with minimal direct cardiac effects.

Non-Dihydropyridines (Cardio-selective): Verapamil (phenylalkylamine), diltiazem (benzothiazepine).

Mechanism: Bind to L-type channels in the myocardium, SA node, and AV node → decrease contractility (negative inotropy), heart rate (negative chronotropy), and conduction velocity (negative dromotropy).

Indications

Dihydropyridines: Hypertension, angina pectoris, Raynaud's phenomenon.

Non-Dihydropyridines: Rate control in atrial fibrillation/flutter, supraventricular tachycardia (SVT) prophylaxis, angina pectoris.

Side Effects

Dihydropyridines: Peripheral edema, reflex tachycardia, flushing, headaches.

Non-Dihydropyridines: Bradycardia, AV block, constipation (especially verapamil), exacerbation of HFrEF.

7. Nitrates

Nitrates are prodrugs that act as potent vasodilators, primarily affecting the venous system.

Mechanisms and Features of Action

Biotransformation: Nitrates (e.g., nitroglycerin, isosorbide dinitrate) are denitrated to release Nitric Oxide (NO).

Intracellular Pathway: NO stimulates soluble guanylyl cyclase → increases intracellular cyclic GMP (cGMP) → activates protein kinase G → dephosphorylation of myosin light chains → smooth muscle relaxation.

Hemodynamic Effects: At therapeutic doses, nitrates cause venous dilation over arterial dilation. This increases venous capacitance, reduces venous return (preload), and lowers left ventricular wall tension, which decreases myocardial oxygen demand. Higher doses cause arterial dilation, reducing afterload.

Nitrate Tolerance: Continuous exposure leads to a depletion of sulfhydryl groups or increased free radical production, neutralizing the drug's effect. A nitrate-free interval of 10-12 hours daily is mandatory to prevent this.

Use

Acute relief and prophylaxis of angina pectoris.
Acute decompensated heart failure (to rapidly reduce preload).
Hypertensive emergencies (intravenous nitroglycerin).

Side Effects

Throbbing headache (due to meningeal artery dilation).
Reflex tachycardia (due to baroreceptor response to blood pressure drops).
Orthostatic hypotension, dizziness, facial flushing.
Contraindication: Absolute contraindication with phosphodiesterase-5 (PDE-5) inhibitors like sildenafil, which can lead to life-threatening hypotension.

8. Lipid-Lowering Agents

Lipid-lowering agents alter plasma lipoprotein metabolism to decrease atherosclerotic plaque formation.

Classification and Principles of Action

HMG-CoA Reductase Inhibitors (Statins): Inhibit cholesterol synthesis.

Cholesterol Absorption Inhibitors: Ezetimibe. Blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestine to lower dietary cholesterol uptake.

PCSK9 Inhibitors: Alirocumab, evolocumab. Monoclonal antibodies that prevent LDL receptor degradation, leaving more receptors available to clear LDL from the blood.

Fibric Acid Derivatives (Fibrates): Fenofibrate, gemfibrozil. Activate PPAR-alpha to upregulate lipoprotein lipase, primarily clearing triglycerides.

Bile Acid Sequestrants: Cholestyramine, colesevelam. Bind bile acids in the gut, forcing the liver to consume plasma cholesterol to synthesize new bile.

Statins: Mechanism, Indications, and Side Effects

Mechanism: Competitively inhibit HMG-CoA reductase. This halts the conversion of HMG-CoA to mevalonate (the rate-limiting step in cholesterol synthesis). Decreased intracellular cholesterol triggers the liver to upregulate surface LDL receptors, removing circulating LDL from the blood.

Indications: Hypercholesterolemia, primary and secondary prevention of cardiovascular events (e.g., myocardial infarction, stroke). [1]

Side Effects: Myalgia, myopathy, rare rhabdomyolysis (risk increases when combined with fibrates or CYP3A4 inhibitors), elevated liver transaminases (hepatotoxicity), and a slight increase in blood glucose levels. Statins are strictly contraindicated in pregnancy.

9. Diuretics: Classification and General Mechanisms

Diuretics increase urine volume by altering the transport of sodium and water across the nephron, thereby lowering blood volume and pressure. [2]

[NEPHRON SITE MAP]
Cortex  (PCT) --> (DCT) ---------+
                                 |
                                 |
                                 v                    v
Medulla (Loop of Henle) -----> (Collecting Duct)

Classification by Site of Nephron Action

Proximal Convoluted Tubule (PCT): Carbonic anhydrase inhibitors, Osmotic diuretics.
Thick Ascending Limb of the Loop of Henle: Loop diuretics.
Distal Convoluted Tubule (DCT): Thiazide and thiazide-like diuretics.
Cortical Collecting Tubule: Potassium-sparing diuretics.

10. Carbonic Anhydrase Inhibitors and Osmotic Diuretics

These agents work early in the nephron but are rarely used for systemic edema due to weak diuretic efficacy.

Carbonic Anhydrase Inhibitors (e.g., Acetazolamide)

Mechanism: Inhibits carbonic anhydrase in the PCT lumen and cytoplasm. This halts the conversion of H₂CO₃ into CO₂ and H₂O, preventing NaHCO₃ reabsorption and forcing sodium and bicarbonate to remain in the urine.

Features: Causes significant alkaline diuresis and metabolic acidosis.

Uses: Glaucoma (reduces aqueous humor production), acute mountain sickness, urinary alkalinization.

Side Effects: Hyperchloremic metabolic acidosis, hypokalemia, kidney stones (calcium phosphate precipitates in alkaline urine), sulfonamide allergy hypersensitivity. [3]

Osmotic Diuretics (e.g., Mannitol) [4]

Mechanism: Mannitol is a non-absorbable solute filtered freely at the glomerulus. It acts along the entire tubule (mainly the PCT and descending loop) to create an osmotic gradient that holds water in the lumen.

Features: It extracts water from intracellular compartments into the bloodstream before it is filtered, expanding extracellular fluid volume initially.

Uses: Reduction of intracranial pressure (cerebral edema), reduction of intraocular pressure.

Side Effects: Transient extracellular volume expansion (can precipitate acute pulmonary edema or heart failure), dehydration, hypernatremia.

11. Loop Diuretics, Thiazides, and Thiazide-Like Diuretics

These are the primary drug classes used to manage volume overload and hypertension.

Loop Diuretics (e.g., Furosemide, Bumetanide, Torsemide)

Mechanism: Reversibly inhibit the Na⁺/K⁺/2Cl⁻ cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. By blocking this transporter, they halt the reabsorption of 25% of the filtered sodium load. They also disrupt the lumen-positive potential, preventing Ca²⁺ and Mg²⁺ reabsorption.

Features: High-ceiling diuretics with potent action. They remain effective even in patients with low glomerular filtration rates (GFR).

Indications: Acute pulmonary edema, chronic heart failure edema, hepatic cirrhosis edema, renal failure edema, severe hypercalcemia.

Side Effects: Hypokalemia, metabolic alkalosis, hypomagnesemia, hypocalcemia, hyperuricemia (gout flare), ototoxicity (hearing loss), sulfonamide allergy.

Thiazide and Thiazide-Like Diuretics (e.g., Hydrochlorothiazide, Chlorthalidone, Indapamide)

Mechanism: Inhibit the Na⁺/Cl⁻ cotransporter (NCC) in the early distal convoluted tubule, blocking 5-10% of sodium reabsorption. This increases distal delivery of sodium, which enhances Ca²⁺ reabsorption in the DCT via the basolateral Na⁺/Ca²⁺ exchanger.

Features: They lose efficacy when GFR drops below 30 mL/min (except indapamide and metolazone).

Indications: Essential hypertension (first-line), mild heart failure edema, nephrogenic diabetes insipidus, calcium nephrolithiasis (hypercalciuria prevention).

Side Effects: Hypokalemia, metabolic alkalosis, hyponatremia, hypercalcemia, hyperuricemia, hyperglycemia, hyperlipidemia.

Now analyse the format or way of answer writing in previous response, now similarly answers the given questions below 👇- DRUGS AFFECTING THE MAJOR ORGANS AND SYSTEMS.1. Antitussives and expectorants: classification, mechanisms and features of action, indications, side effects.2. Bronchodilators: classification, mechanisms of action, treatment of bronchial asthma and other broncho-obstructive syndrome, side effects.3. Cardiac glycosides: mechanisms of action on the heart rate, the conductive system of the heart, hemodynamics and renal function. Indications.4. Glycoside intoxication (Digitalis Toxicity): stages, pathogenesis, symptoms, management.5. Antiarrhythmic agents I: mechanisms of action, indications, side effects.6. Calcium channel blockers: classification, mechanisms of action, indications, side effects.7. Nitrates: mechanisms and features of action, use, side effects. 8. Lipid-lowering agents: principles of action, classification. Mechanisms of action, indications, side effects of statins.9. Diuretics: mechanisms of action, classification.10.The carbonic anhydrase inhibitors and osmotic diuretics: mechanisms and features of action, uses, side effects.11.Loop diuretics, thiazides and thiazide-like diuretics: mechanisms and features of action, indications, side effects.12.Potassium-sparing diuretics: mechanisms and features of action, use, side effects.13.ACE inhibitors: mechanisms of action, indications, side effects. 14.AT1-receptor blockers: mechanisms of action, indications, side effects. 15.Antiemetic agents: classification, mechanisms and principles of action, indications, side effects.16.Drugs that reduce gastric acidity: classification, mechanisms and features of action, indications, side effects.17.Laxatives: classification, mechanisms of action, use, side effects.18.Drugs affecting the uterus: classification, mechanisms and features of action, indications, side effects.19.Antiplatelet agents: classification, mechanisms and features of action, indications, side effects.20.Heparin: origin, chemical structure, mechanisms and features of action, indications, side effects. Direct inhibitors of thrombin and Xa factor.21.Low molecular weight heparins: mechanisms and features of action, indications, side effects.22.Warfarin: mechanisms and features of action, indications, side effects.23.Thrombolytic drugs: mechanisms of action, therapeutic use, adverse effects.24.Fibrinolytic agents: classification, mechanisms of action, clinical use, side effects.25.Iron drugs: metabolism of iron, classification, mechanisms of action, clinical use, side effects.26.Cyanocobalamin (Vitamin B12): oral metabolism, clinical uses, side effects27.Drugs for diabetes mellitus type 1: insulin and insulin analogues.28.Drugs for diabetes mellitus type 2: classification, mechanisms of action, adverse effects.

Start from question 1 up to question 28

Here is the complete answer set, questions 1 through 28, written in the same format as the previous response.

1. Antitussives and Expectorants

These agents manage respiratory conditions by either suppressing the cough reflex or facilitating mucus clearance.

Classification and Mechanisms

Central Antitussives (Opioids): Codeine, dextromethorphan. They suppress the cough center in the medulla oblongata.

Peripheral Antitussives: Prenoxdiazine, levodropropizine. They reduce the sensitivity of respiratory tract stretch receptors.

Secretomotor Expectorants: Ammonium chloride, potassium iodide. They irritate the gastric mucosa to reflexively increase bronchial secretions.

Mucolytics: N-acetylcysteine, ambroxol, bromhexine. N-acetylcysteine breaks disulfide bonds in mucoproteins to liquefy mucus. Ambroxol stimulates surfactant production.

Indications

Antitussives: Dry, non-productive, exhausting coughs (e.g., post-viral cough, lung cancer).

Expectorants/Mucolytics: Productive coughs with thick, viscous sputum (e.g., bronchitis, COPD, cystic fibrosis).

Side Effects

Opioid Antitussives: Sedation, constipation, respiratory depression, addiction potential.

Expectorants/Mucolytics: Gastrointestinal irritation, nausea, bronchospasm (especially with inhaled mucolytics in asthmatics).

2. Bronchodilators

Bronchodilators relax bronchial smooth muscle to reverse airway obstruction.

Classification and Mechanisms

β₂-Adrenergic Agonists:

SABA (Short-Acting): Salbutamol, albuterol.
LABA (Long-Acting): Salmeterol, formoterol.
Mechanism: Stimulate β₂-receptors → activate adenylyl cyclase → increase cAMP → smooth muscle relaxation.

Anticholinergics (Muscarinic Antagonists):

SAMA: Ipratropium bromide.
LAMA: Tiotropium bromide.
Mechanism: Block M₃ muscarinic receptors → inhibit vagal bronchoconstriction and mucus secretion.

Methylxanthines: Theophylline, aminophylline.

Mechanism: Inhibit phosphodiesterase (PDE), increasing cAMP. They also block adenosine receptors.

Treatment of Asthma and Broncho-Obstructive Syndromes

Acute Asthma Exacerbation: Fast-acting SABAs (salbutamol) serve as first-line rescue therapy, often combined with SAMAs (ipratropium).

Chronic Asthma Maintenance: Formoterol or salmeterol are used, always paired with an inhaled corticosteroid (ICS) to manage inflammation.

COPD Management: LAMAs and LABAs are the foundational maintenance therapies to minimize air trapping.

Side Effects

β₂-Agonists: Skeletal muscle tremors, tachycardia, palpitations, hypokalemia.

Anticholinergics: Dry mouth, urinary retention, blurred vision, constipation.

Methylxanthines: Narrow therapeutic window. Causes insomnia, severe arrhythmias, seizures, and vomiting.

3. Cardiac Glycosides

Cardiac glycosides (e.g., Digoxin) are positive inotropic and negative chronotropic agents derived from Digitalis plants.

Mechanisms of Action

Hemodynamics: Increases cardiac output in failing hearts, lowers left ventricular end-diastolic pressure, and reduces systemic vascular resistance via baroreceptor restoration.

Renal Function: Increased cardiac output improves renal perfusion. This promotes diuresis and reduces renin-angiotensin-aldosterone system (RAAS) activation.

Indications

Chronic heart failure with reduced ejection fraction (HFrEF) symptomatic despite optimal therapy.
Ventricular rate control in patients with atrial fibrillation or atrial flutter.

4. Glycoside Intoxication (Digitalis Toxicity)

Digoxin has a very narrow therapeutic index (0.5 - 2.0 ng/mL), making toxicity a frequent clinical challenge.

Pathogenesis and Contributing Factors

Stages and Symptoms

Gastrointestinal (Early): Anorexia, nausea, vomiting, abdominal pain.

Neurological/Visual: Fatigue, confusion, delirium, xanthopsia (yellow-green halos around lights).

Management

Discontinuation: Stop digoxin and any potassium-wasting diuretics immediately.
Electrolyte Correction: Administer potassium if hypokalemia is present (maintain normal-to-high levels, provided there is no high-degree AV block).
Antiarrhythmics: Phenytoin or lidocaine are preferred for digitalis-induced ventricular arrhythmias. Avoid Class IA agents and calcium channel blockers.
Specific Antidote: Administer Digoxin-specific antibody fragments (DigiFab) for life-threatening arrhythmias, severe hyperkalemia, or massive overdoses.

5. Antiarrhythmic Agents - Class I

Class I antiarrhythmics block voltage-gated sodium channels (Na⁺ channels) during Phase 0 of the cardiac action potential.

Classification and Mechanisms

Class IB (Weak block; shortens repolarization): Lidocaine, mexiletine. They bind preferentially to inactivated Na⁺ channels in ischemic tissues, shortening APD.

Class IC (Strong block; no effect on repolarization): Flecainide, propafenone. They markedly slow Phase 0 depolarization and significantly decrease conduction velocity with minimal effect on APD.

Action Potential	Phase 0 Depolarization Slope
Normal	/
Class IB Alteration	/ (Mild decrease)
Class IA Alteration	/ (Moderate decrease)
Class IC Alteration	/ (Severe flattening)

Indications

Class IA: Atrial fibrillation rhythm control, ventricular tachycardia.

Class IB: Acute ventricular arrhythmias, particularly post-myocardial infarction or digitalis-induced.

Class IC: Supraventricular tachycardias (SVT), atrial fibrillation in patients without structural heart disease.

Side Effects

Class IA: Torsades de pointes (due to prolonged QT), drug-induced lupus (procainamide), cinchonism (quinidine).

Class IB: CNS toxicity (confusion, paresthesias, seizures, slurred speech).

Class IC: Highly proarrhythmic (especially post-MI, as demonstrated in the CAST trial), metallic taste (propafenone).

6. Calcium Channel Blockers (CCBs)

CCBs inhibit the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac cells.

Classification and Mechanisms

Dihydropyridines (Vascular-selective): Amlodipine, nifedipine, felodipine.

Mechanism: Bind to vascular smooth muscle L-type channels → cause marked peripheral vasodilation with minimal direct cardiac effects.

Non-Dihydropyridines (Cardio-selective): Verapamil (phenylalkylamine), diltiazem (benzothiazepine).

Mechanism: Bind to L-type channels in the myocardium, SA node, and AV node → decrease contractility (negative inotropy), heart rate (negative chronotropy), and conduction velocity (negative dromotropy).

Indications

Dihydropyridines: Hypertension, angina pectoris, Raynaud's phenomenon.

Non-Dihydropyridines: Rate control in atrial fibrillation/flutter, supraventricular tachycardia (SVT) prophylaxis, angina pectoris.

Side Effects

Dihydropyridines: Peripheral edema, reflex tachycardia, flushing, headaches.

Non-Dihydropyridines: Bradycardia, AV block, constipation (especially verapamil), exacerbation of HFrEF.

7. Nitrates

Nitrates are prodrugs that act as potent vasodilators, primarily affecting the venous system.

Mechanisms and Features of Action

Biotransformation: Nitrates (e.g., nitroglycerin, isosorbide dinitrate) are denitrated to release Nitric Oxide (NO).

Use

Acute relief and prophylaxis of angina pectoris.
Acute decompensated heart failure (to rapidly reduce preload).
Hypertensive emergencies (intravenous nitroglycerin).

Side Effects

Throbbing headache (due to meningeal artery dilation).
Reflex tachycardia (due to baroreceptor response to blood pressure drops).
Orthostatic hypotension, dizziness, facial flushing.
Contraindication: Absolute contraindication with phosphodiesterase-5 (PDE-5) inhibitors like sildenafil, which can lead to life-threatening hypotension.

8. Lipid-Lowering Agents

Lipid-lowering agents alter plasma lipoprotein metabolism to decrease atherosclerotic plaque formation.

Classification and Principles of Action

HMG-CoA Reductase Inhibitors (Statins): Inhibit cholesterol synthesis.

Cholesterol Absorption Inhibitors: Ezetimibe. Blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestine to lower dietary cholesterol uptake.

PCSK9 Inhibitors: Alirocumab, evolocumab. Monoclonal antibodies that prevent LDL receptor degradation, leaving more receptors available to clear LDL from the blood.

Fibric Acid Derivatives (Fibrates): Fenofibrate, gemfibrozil. Activate PPAR-alpha to upregulate lipoprotein lipase, primarily clearing triglycerides.

Bile Acid Sequestrants: Cholestyramine, colesevelam. Bind bile acids in the gut, forcing the liver to consume plasma cholesterol to synthesize new bile.

Statins: Mechanism, Indications, and Side Effects

Indications: Hypercholesterolemia, primary and secondary prevention of cardiovascular events (e.g., myocardial infarction, stroke).

9. Diuretics: Classification and General Mechanisms

Diuretics increase urine volume by altering the transport of sodium and water across the nephron, thereby lowering blood volume and pressure.

[NEPHRON SITE MAP]
Cortex  (PCT) --> (DCT) ---------+
                                 |
                                 v                    v
Medulla (Loop of Henle) -----> (Collecting Duct)

Classification by Site of Nephron Action

Proximal Convoluted Tubule (PCT): Carbonic anhydrase inhibitors, Osmotic diuretics.
Thick Ascending Limb of the Loop of Henle: Loop diuretics.
Distal Convoluted Tubule (DCT): Thiazide and thiazide-like diuretics.
Cortical Collecting Tubule: Potassium-sparing diuretics.

10. Carbonic Anhydrase Inhibitors and Osmotic Diuretics

These agents work early in the nephron but are rarely used for systemic edema due to weak diuretic efficacy.

Carbonic Anhydrase Inhibitors (e.g., Acetazolamide)

Features: Causes significant alkaline diuresis and metabolic acidosis.

Uses: Glaucoma (reduces aqueous humor production), acute mountain sickness, urinary alkalinization.

Side Effects: Hyperchloremic metabolic acidosis, hypokalemia, kidney stones (calcium phosphate precipitates in alkaline urine), sulfonamide allergy hypersensitivity.

Osmotic Diuretics (e.g., Mannitol)

Features: It extracts water from intracellular compartments into the bloodstream before it is filtered, expanding extracellular fluid volume initially.

Uses: Reduction of intracranial pressure (cerebral edema), reduction of intraocular pressure.

Side Effects: Transient extracellular volume expansion (can precipitate acute pulmonary edema or heart failure), dehydration, hypernatremia.

11. Loop Diuretics, Thiazides, and Thiazide-Like Diuretics

These are the primary drug classes used to manage volume overload and hypertension.

Loop Diuretics (e.g., Furosemide, Bumetanide, Torsemide)

Features: High-ceiling diuretics with potent action. They remain effective even in patients with low glomerular filtration rates (GFR).

Indications: Acute pulmonary edema, chronic heart failure edema, hepatic cirrhosis edema, renal failure edema, severe hypercalcemia.

Side Effects: Hypokalemia, metabolic alkalosis, hypomagnesemia, hypocalcemia, hyperuricemia (gout flare), ototoxicity (hearing loss), sulfonamide allergy.

Thiazide and Thiazide-Like Diuretics (e.g., Hydrochlorothiazide, Chlorthalidone, Indapamide)

Features: They lose efficacy when GFR drops below 30 mL/min (except indapamide and metolazone).

Indications: Essential hypertension (first-line), mild heart failure edema, nephrogenic diabetes insipidus, calcium nephrolithiasis (hypercalciuria prevention).

Side Effects: Hypokalemia, metabolic alkalosis, hyponatremia, hypercalcemia, hyperuricemia, hyperglycemia, hyperlipidemia.

12. Potassium-Sparing Diuretics

These agents act on the cortical collecting tubule to promote sodium excretion while retaining potassium, producing a weak but potassium-conserving diuresis.

Classification and Mechanisms

Aldosterone Antagonists (Competitive): Spironolactone, eplerenone.

Mechanism: Competitively block mineralocorticoid (aldosterone) receptors in the principal cells of the collecting duct. This prevents aldosterone from upregulating Na⁺/K⁺-ATPase pumps and epithelial sodium channels (ENaC), reducing sodium reabsorption and potassium secretion.
Feature: Spironolactone has anti-androgenic side effects due to steroid receptor cross-reactivity. Eplerenone is more selective and avoids this.

Epithelial Sodium Channel (ENaC) Blockers: Amiloride, triamterene.

Mechanism: Directly block ENaC channels in the luminal membrane of collecting duct principal cells, independent of aldosterone. This reduces sodium entry into the cell, decreasing the electrochemical gradient that drives potassium secretion into the tubule.
Feature: Their effect is not influenced by aldosterone levels, making them useful in all clinical contexts.

Use

Combined with loop diuretics or thiazides to prevent hypokalemia (potassium-sparing combination therapy).
Spironolactone: Heart failure with reduced ejection fraction (HFrEF) - reduces mortality. Primary hyperaldosteronism (Conn's syndrome) diagnosis and management. Liver cirrhosis with ascites.
Amiloride: Adjunct in hypertension, lithium-induced nephrogenic diabetes insipidus.

Side Effects

All Potassium-Sparing Diuretics: Hyperkalemia (the primary risk - dangerous in renal impairment or with ACE inhibitors/ARBs). Contraindicated in patients with significant renal insufficiency.

Spironolactone (anti-androgenic effects): Gynecomastia, impotence, and decreased libido in men; menstrual irregularities in women.

Triamterene: Kidney stones (triamterene crystallizes in alkaline urine), megaloblastic anemia (folate antagonism).

Amiloride: Generally well tolerated beyond the risk of hyperkalemia.

13. ACE Inhibitors

ACE inhibitors block the renin-angiotensin-aldosterone system (RAAS) at the level of angiotensin-converting enzyme (ACE), reducing angiotensin II production and bradykinin breakdown.

Mechanisms of Action

RAAS Blockade: ACE converts angiotensin I to angiotensin II (a potent vasoconstrictor). ACE inhibitors (e.g., enalapril, lisinopril, ramipril, captopril) competitively inhibit ACE → angiotensin II levels fall → AT₁ receptors are not activated → arteriolar and venous dilation → reduced afterload and preload → decreased blood pressure.

Aldosterone Reduction: Lower angiotensin II reduces aldosterone secretion from the adrenal cortex → less sodium and water retention → decreased circulating volume.

Bradykinin Accumulation: ACE also degrades bradykinin. ACE inhibition allows bradykinin to accumulate → additional vasodilation (via NO and prostaglandin release) → contributes to blood pressure reduction but also causes the characteristic dry cough and, rarely, angioedema.

Renal Effects: Angiotensin II preferentially constricts the efferent arteriole of the glomerulus. ACE inhibitors dilate the efferent arteriole → reduce intraglomerular pressure → long-term renoprotection in diabetic and hypertensive nephropathy.

Indications

Hypertension (first-line, especially with diabetes or chronic kidney disease).
Heart failure with reduced ejection fraction (HFrEF) - reduces mortality and hospitalizations.
Post-myocardial infarction (reduces ventricular remodeling).
Diabetic nephropathy and non-diabetic proteinuric renal disease (renoprotection).

Side Effects

Dry, persistent cough (bradykinin accumulation - most common reason for discontinuation; switch to ARB).
Angioedema (rare but potentially life-threatening; bradykinin-mediated swelling of lips, tongue, larynx - absolute contraindication to re-challenge).
Hyperkalemia (reduced aldosterone → potassium retention; caution with potassium-sparing diuretics).
First-dose hypotension (especially in volume-depleted patients).
Acute kidney injury (in patients with bilateral renal artery stenosis - removing efferent constriction causes a critical drop in GFR).
Teratogenic: Contraindicated in pregnancy (causes fetal renal dysgenesis, oligohydramnios, limb defects).

14. AT₁-Receptor Blockers (ARBs)

Angiotensin receptor blockers (ARBs) selectively block the AT₁ receptor, the main receptor mediating the harmful effects of angiotensin II, producing a pharmacological profile almost identical to ACE inhibitors but without bradykinin accumulation.

Mechanisms of Action

AT₁ Receptor Blockade: ARBs (e.g., losartan, valsartan, candesartan, irbesartan) bind selectively and competitively to AT₁ receptors on vascular smooth muscle, adrenal cortex, kidney, and heart. This directly prevents angiotensin II from causing:

Vasoconstriction → blood pressure falls.
Aldosterone release → sodium and water excretion increases.
Sympathetic nervous system activation → heart rate and cardiac output are reduced.

Key Difference from ACE Inhibitors: ARBs do not inhibit ACE, so bradykinin is not accumulated. Angiotensin II is still produced but cannot act on the AT₁ receptor. Angiotensin II may instead act on the AT₂ receptor, which mediates vasodilation and anti-proliferative effects.

Indications

Hypertension (first-line alternative to ACE inhibitors, particularly when ACE inhibitor-induced cough occurs).
Heart failure with reduced ejection fraction (HFrEF) - especially as ACE inhibitor substitute.
Post-myocardial infarction (valsartan, candesartan).
Diabetic nephropathy (losartan, irbesartan have specific evidence for renal protection in type 2 diabetics).
Prevention of stroke in hypertensive patients with left ventricular hypertrophy (losartan).

Side Effects

Hyperkalemia (same mechanism as ACE inhibitors - reduced aldosterone).
Hypotension (first-dose effect, especially in volume-depleted patients).
Acute kidney injury (same risk as ACE inhibitors in bilateral renal artery stenosis).
No dry cough - this is the main clinical advantage over ACE inhibitors.
Angioedema - extremely rare (much less than ACE inhibitors) but can occasionally occur.
Teratogenic: Contraindicated in pregnancy (same fetal risks as ACE inhibitors).

15. Antiemetic Agents

Antiemetics suppress nausea and vomiting by acting on the multiple neurotransmitter pathways that converge on the vomiting center in the medulla and the chemoreceptor trigger zone (CTZ) in the area postrema.

Classification and Mechanisms

Dopamine D₂ Receptor Antagonists:

Metoclopramide, domperidone, haloperidol, prochlorperazine.
Mechanism: Block D₂ receptors in the CTZ (area postrema), suppressing the dopaminergic vomiting signal. Metoclopramide also enhances gastric motility (prokinetic effect) by increasing acetylcholine release in the gut.
Feature: Domperidone does not cross the blood-brain barrier well, so it has fewer central extrapyramidal side effects than metoclopramide.

5-HT₃ (Serotonin) Receptor Antagonists:

Ondansetron, granisetron, tropisetron.
Mechanism: Block 5-HT₃ receptors on vagal afferents in the gut and in the CTZ. Chemotherapy and radiation release serotonin from enterochromaffin cells in the gut, which triggers vomiting via these receptors. Blocking them is highly effective against chemotherapy-induced nausea.

NK₁ (Neurokinin-1) Receptor Antagonists:

Aprepitant, fosaprepitant.
Mechanism: Block substance P at NK₁ receptors in the vomiting center. Primarily used for delayed chemotherapy-induced nausea and vomiting (CINV) - often combined with a 5-HT₃ antagonist and a corticosteroid (dexamethasone) for maximal antiemetic coverage.

H₁ Antihistamines:

Dimenhydrinate, promethazine, meclizine.
Mechanism: Block H₁ receptors in the vestibular nuclei and vomiting center, reducing motion-induced nausea signals. They also have anticholinergic properties that contribute to their antiemetic effect.

Anticholinergics (Muscarinic Antagonists):

Scopolamine (hyoscine).
Mechanism: Block muscarinic receptors in the vestibular apparatus and vomiting center, interrupting motion sickness signals. Administered as a transdermal patch for sustained effect.

Corticosteroids:

Dexamethasone.
Mechanism: Not fully defined, but involves inhibition of prostaglandin synthesis and modulation of serotonin signaling. Used adjunctively in CINV regimens.

Indications

Ondansetron/Granisetron: Chemotherapy-induced and radiotherapy-induced nausea and vomiting (CINV); postoperative nausea and vomiting (PONV).
Aprepitant: Delayed phase CINV (combined with 5-HT₃ antagonist + dexamethasone).
Metoclopramide: Gastroparesis, postoperative nausea, CINV (weaker), gastroesophageal reflux.
Dimenhydrinate/Scopolamine: Motion sickness, vestibular-induced vomiting (Meniere's disease).
Domperidone: Nausea in Parkinson's disease patients (does not worsen motor symptoms), gastroparesis.

Side Effects

D₂ Antagonists (Metoclopramide): Extrapyramidal symptoms (acute dystonia, akathisia, tardive dyskinesia with prolonged use), hyperprolactinemia (galactorrhea, amenorrhea), drowsiness.

5-HT₃ Antagonists: Headache, constipation, QT prolongation (especially ondansetron at high doses).

NK₁ Antagonists: Fatigue, hiccups, elevated liver enzymes. Aprepitant is a CYP3A4 inhibitor - significant drug interactions.

H₁ Antihistamines: Sedation, dry mouth, urinary retention, blurred vision (anticholinergic effects).

Scopolamine: Dry mouth, blurred vision, confusion (particularly in the elderly), drowsiness.

16. Drugs That Reduce Gastric Acidity

These agents lower intragastric acid concentration through different mechanisms, treating acid-related disorders such as peptic ulcer disease (PUD), GERD, and Helicobacter pylori infection.

Classification and Mechanisms

Proton Pump Inhibitors (PPIs):

Omeprazole, pantoprazole, lansoprazole, esomeprazole.
Mechanism: Prodrugs that are activated in the acidic canaliculi of parietal cells. The active form (sulfenamide) irreversibly binds and inhibits the H⁺/K⁺-ATPase (proton pump) - the final step of acid secretion. A new pump must be synthesized before acid secretion resumes (48-72 hours for full effect). PPIs are the most potent acid suppressants available.
Feature: Must be taken 30 minutes before meals to ensure the pump is active and the prodrug can reach its binding site.

H₂ Receptor Antagonists (H₂RAs):

Ranitidine, famotidine, cimetidine.
Mechanism: Competitively block histamine H₂ receptors on parietal cells, reducing histamine-stimulated cAMP production and gastric acid output. Effective but less potent than PPIs. Tolerance (tachyphylaxis) develops with continuous use.

Antacids:

Aluminum hydroxide, magnesium hydroxide, calcium carbonate (Maalox, Tums).
Mechanism: Neutralize already-secreted hydrochloric acid by direct chemical reaction. They do not reduce acid production. Provide rapid but short-lived symptom relief.
Feature: Aluminum salts cause constipation; magnesium salts cause diarrhea. Combined preparations balance these effects.

Mucosal Protective Agents (Cytoprotective Agents):

Sucralfate: A sulfated polysaccharide that, in an acid environment, polymerizes and forms a viscous paste that adheres to ulcer craters, protecting them from acid and pepsin.
Bismuth subcitrate: Coats ulcer craters, has bactericidal activity against H. pylori, and inhibits pepsin.
Misoprostol: A synthetic prostaglandin E₁ analogue. Stimulates mucus and bicarbonate secretion and inhibits acid secretion via EP₃ receptors. Primarily used to prevent NSAID-induced gastropathy.

Indications

PPIs: First-line for GERD, peptic ulcer disease (including H. pylori eradication regimens), Zollinger-Ellison syndrome, stress ulcer prophylaxis, NSAID-induced ulcer prevention.
H₂RAs: GERD (mild-moderate), peptic ulcers, stress ulcer prophylaxis (ICU patients), nocturnal acid breakthrough (added to PPI therapy).
Antacids: Symptomatic relief of heartburn and dyspepsia.
Sucralfate: Peptic ulcer healing, stress ulcer prophylaxis.
Misoprostol: Prevention of NSAID-induced gastric ulcers (especially in high-risk patients).

Side Effects

PPIs: Generally well tolerated. Long-term use: hypomagnesemia, hypokalemia, increased risk of Clostridium difficile infection, increased risk of community-acquired pneumonia, osteoporosis and bone fractures (reduced calcium absorption in achlorhydric state), rebound acid hypersecretion upon abrupt discontinuation, potential vitamin B12 malabsorption.

H₂RAs: Headache, dizziness. Cimetidine specifically: gynecomastia and impotence (anti-androgenic effects), significant CYP450 enzyme inhibition causing multiple drug interactions.

Antacids: Constipation (aluminum), diarrhea (magnesium), milk-alkali syndrome (calcium carbonate with high dairy intake), impaired absorption of other drugs (tetracyclines, fluoroquinolones, iron).

Misoprostol: Diarrhea (dose-dependent), abdominal cramping. Contraindicated in pregnancy (causes uterine contractions and abortion).

17. Laxatives

Laxatives promote bowel movements by various mechanisms acting on the colon's motility, secretion, or luminal content.

Classification and Mechanisms

Bulk-Forming Laxatives:

Psyllium (ispaghula husk), methylcellulose, bran.
Mechanism: Poorly absorbed hydrophilic polysaccharides that absorb water and swell in the colon, increasing stool bulk and volume. The distension stimulates peristalsis by activating stretch receptors in the colon wall.
Feature: Safest long-term option; must be taken with adequate water to avoid intestinal obstruction.

Osmotic Laxatives:

Lactulose, polyethylene glycol (PEG/macrogol), magnesium hydroxide (milk of magnesia), sorbitol.
Mechanism: Non-absorbable or poorly absorbed solutes that retain water in the intestinal lumen by osmosis, increasing luminal fluid volume and stimulating bowel activity. Lactulose is also metabolized by colonic bacteria to short-chain fatty acids, acidifying the colon - this traps ammonia (NH₄⁺) in the gut, making it useful in hepatic encephalopathy.

Stimulant (Contact) Laxatives:

Bisacodyl, sodium picosulfate, senna (anthraquinone), castor oil.
Mechanism: Directly stimulate enteric nervous system neurons and irritate colonic mucosal nerve endings → increase propulsive peristaltic contractions. They also inhibit water and electrolyte absorption in the colon. Senna is converted by gut bacteria to active anthrones that stimulate the myenteric plexus.

Stool Softeners (Emollient Laxatives):

Docusate sodium.
Mechanism: Act as detergents (anionic surfactants) that reduce surface tension, allowing water and lipids to penetrate the stool mass and soften it. They have weak intrinsic laxative effect.

Lubricant Laxatives:

Liquid paraffin (mineral oil).
Mechanism: Coat fecal material and the intestinal mucosa with a water-immiscible film, preventing water reabsorption from the stool and lubricating its passage.
Feature: Long-term use risks lipid pneumonia (aspiration), malabsorption of fat-soluble vitamins (A, D, E, K).

Use

Bulk-forming: Chronic constipation, irritable bowel syndrome (IBS-C), to normalize bowel habits (safe in pregnancy).
Osmotic (Lactulose): Constipation, hepatic encephalopathy (reducing ammonia absorption).
Osmotic (PEG): Chronic constipation, bowel preparation before colonoscopy.
Stimulant: Short-term relief of acute constipation, bowel preparation for procedures.
Docusate: Post-surgical or post-myocardial infarction constipation (avoids straining).

Side Effects

Bulk-forming: Bloating, flatulence, intestinal obstruction if taken without sufficient water.

Osmotic (Lactulose): Flatulence, bloating, abdominal cramps, diarrhea (dose-dependent).

Osmotic (Magnesium-based): Hypermagnesemia in renal failure patients.

Stimulant: Abdominal cramping, electrolyte imbalances with chronic use (hypokalemia), melanosis coli (harmless pigmentation with anthraquinone laxatives), risk of laxative dependence and colonic dysmotility with prolonged overuse.

Liquid Paraffin: Lipid pneumonia (aspiration), malabsorption of fat-soluble vitamins, perianal leakage.

18. Drugs Affecting the Uterus

These agents modify myometrial contractility, either stimulating (uterotonics/oxytocics) or inhibiting (tocolytics) uterine contractions.

Classification and Mechanisms

Uterotonics (Oxytocics):

Oxytocin and Analogues:

Oxytocin (synthetic), carbetocin (long-acting oxytocin analogue).
Mechanism: Bind to G-protein-coupled oxytocin receptors (Gq) on myometrial cells → activate phospholipase C → increase inositol triphosphate (IP₃) and intracellular Ca²⁺ → stimulate uterine smooth muscle contraction. Receptor density increases dramatically at term, explaining why oxytocin is more effective near delivery.
Feature: Short half-life (~5 minutes); carbetocin has a longer duration (~1 hour).

Ergot Alkaloids:

Ergometrine (ergonovine), methylergometrine.
Mechanism: Partial agonists at serotonin (5-HT₂), dopamine, and alpha-adrenergic receptors on the uterus. Produce sustained, tetanic uterine contractions (not rhythmic), making them unsuitable for labor induction but highly effective at controlling postpartum hemorrhage.
Feature: Cause significant vasoconstriction (both uterine and systemic).

Prostaglandins:

Dinoprostone (PGE₂), carboprost (PGF₂α), misoprostol (PGE₁ analogue).
Mechanism: Bind prostaglandin receptors (EP and FP) on myometrial cells → increase intracellular Ca²⁺ → uterine contractions. PGE₂ also causes cervical ripening (softening and dilation) by stimulating collagenase activity.

Tocolytics (Uterine Relaxants):

β₂-Adrenergic Agonists:

Ritodrine, terbutaline, salbutamol.
Mechanism: Stimulate β₂-receptors on myometrium → increase cAMP → activate protein kinase A → phosphorylate myosin light chain kinase → reduce its activity → relax uterine smooth muscle.

Calcium Channel Blockers:

Nifedipine.
Mechanism: Block L-type Ca²⁺ channels in myometrial cells → reduce intracellular Ca²⁺ → inhibit uterine contractions. Currently preferred over β₂-agonists due to superior tolerability.

Oxytocin Receptor Antagonists:

Atosiban.
Mechanism: Competitively block oxytocin receptors on the myometrium, directly inhibiting oxytocin-induced contractions. Highly selective with minimal systemic side effects.

Magnesium Sulfate:

Mechanism: Competes with Ca²⁺ at the myometrial cell membrane, reducing contractility. Also used for neuroprotection of the preterm fetus (reduces risk of cerebral palsy).

Indications

Uterotonics:

Oxytocin: Induction and augmentation of labor at term; prevention and treatment of postpartum hemorrhage (first-line).
Ergometrine/Methylergometrine: Prevention and treatment of postpartum hemorrhage (second-line; not used in labor induction due to tetanic contractions).
Dinoprostone/Misoprostol: Cervical ripening and labor induction; medical abortion (misoprostol combined with mifepristone); postpartum hemorrhage management.

Tocolytics:

Prevention of preterm labor (to delay delivery and allow corticosteroid administration for fetal lung maturation).
Nifedipine and atosiban are current first-line tocolytics.

Side Effects

Oxytocin: Water retention and hyponatremia (antidiuretic effect at high doses), hypotension (vasodilation), uterine hyperstimulation and fetal distress, uterine rupture.

Ergometrine: Nausea, vomiting, hypertension (contraindicated in pre-eclampsia/hypertension), severe vasospasm (coronary artery spasm - contraindicated in ischemic heart disease).

Carboprost (PGF₂α): Bronchospasm (contraindicated in asthma), nausea, vomiting, diarrhea, flushing, fever.

β₂-Agonist Tocolytics: Maternal tachycardia, palpitations, hyperglycemia, hypokalemia, pulmonary edema (with IV administration).

Nifedipine (tocolytic): Maternal hypotension, headache, flushing, reflex tachycardia.

Atosiban: Nausea, injection-site reactions; generally well tolerated.

Magnesium Sulfate: Flushing, muscle weakness, respiratory depression, cardiac arrest at toxic levels (monitor deep tendon reflexes; antidote is calcium gluconate).

19. Antiplatelet Agents

Antiplatelet agents reduce platelet aggregation and thrombus formation in arterial circulation, where platelets are the primary drivers of clot formation.

Classification and Mechanisms

Cyclooxygenase (COX) Inhibitors:

Aspirin (acetylsalicylic acid).
Mechanism: Irreversibly acetylates and inhibits COX-1 (and COX-2) in platelets → prevents synthesis of thromboxane A₂ (TXA₂), a potent platelet activator and vasoconstrictor. Because platelets lack nuclei, they cannot synthesize new COX enzyme - the antiplatelet effect lasts the entire platelet lifetime (7-10 days).
Feature: Low-dose aspirin (75-150 mg) preferentially inhibits platelet TXA₂ production while largely sparing endothelial prostacyclin (PGI₂) synthesis.

ADP P2Y₁₂ Receptor Antagonists:

Thienopyridines (prodrugs requiring hepatic activation):

Clopidogrel, prasugrel, ticlopidine.
Mechanism: Irreversibly block the P2Y₁₂ ADP receptor on platelets after conversion to active metabolites by CYP enzymes (primarily CYP2C19 for clopidogrel). Blocking P2Y₁₂ prevents ADP-mediated platelet activation and aggregation.

Direct-acting (no hepatic activation required):

Ticagrelor (reversible), cangrelor (reversible, IV).
Mechanism: Directly and reversibly block P2Y₁₂ receptors. Ticagrelor has a faster onset and more consistent antiplatelet effect than clopidogrel (not dependent on CYP2C19 polymorphism).

Glycoprotein IIb/IIIa (GP IIb/IIIa) Receptor Antagonists:

Abciximab (monoclonal antibody), eptifibatide (cyclic peptide), tirofiban (non-peptide).
Mechanism: Block the GP IIb/IIIa receptor on the platelet surface, the final common pathway of platelet aggregation. This receptor normally binds fibrinogen, cross-linking adjacent platelets. Blocking it prevents aggregation regardless of the activating stimulus.
Feature: IV use only; used in high-risk percutaneous coronary interventions (PCI).

Phosphodiesterase Inhibitors:

Dipyridamole, cilostazol.
Mechanism: Inhibit phosphodiesterase → increase intracellular cAMP → suppress platelet activation. Dipyridamole also inhibits adenosine reuptake, raising extracellular adenosine levels (vasodilation and platelet inhibition). Cilostazol also dilates peripheral arteries.

Indications

Aspirin: Primary and secondary prevention of myocardial infarction and ischemic stroke, stable coronary artery disease, acute coronary syndrome (ACS), post-PCI and post-stent placement.
Clopidogrel/Ticagrelor/Prasugrel: ACS (dual antiplatelet therapy - DAPT - combined with aspirin), post-coronary stent implantation (prevents in-stent thrombosis), peripheral arterial disease.
GP IIb/IIIa Antagonists: High-risk PCI procedures, non-ST-elevation ACS managed invasively.
Dipyridamole + Aspirin: Secondary prevention of ischemic stroke and TIA.
Cilostazol: Peripheral arterial disease with intermittent claudication.

Side Effects

Aspirin: Gastrointestinal bleeding and peptic ulceration (especially at higher doses), bleeding (risk with any invasive procedure), hypersensitivity (aspirin-exacerbated respiratory disease - bronchospasm in susceptible asthmatics), Reye's syndrome in children (avoid in viral illness under age 16), tinnitus and hearing loss at toxic doses (salicylism).

Thienopyridines (Clopidogrel): Bleeding, rash. Rare but serious: thrombotic thrombocytopenic purpura (TTP) with ticlopidine (less common with clopidogrel). Variable response with clopidogrel due to CYP2C19 polymorphisms.

Ticagrelor: Bleeding, dyspnea (adenosine-mediated, usually transient), bradycardia, elevated uric acid.

GP IIb/IIIa Antagonists: Bleeding (major concern), thrombocytopenia.

Cilostazol: Headache, palpitations, diarrhea. Contraindicated in heart failure (any severity).

20. Heparin: Origin, Structure, Mechanisms, Indications, Side Effects. Direct Thrombin and Xa Inhibitors

Heparin

Origin and Chemical Structure: Heparin is a naturally occurring glycosaminoglycan (mucopolysaccharide) isolated from bovine lung or porcine intestinal mucosa. It consists of alternating residues of sulfated glucosamine and glucuronic/iduronic acid, with molecular weights ranging from 3,000 to 30,000 Da (mean ~15,000 Da). The key functional unit is a specific pentasaccharide sequence that binds antithrombin III (AT-III).

Mechanism of Action:

Heparin binds to antithrombin III (AT-III), inducing a conformational change that dramatically accelerates AT-III's natural inhibitory activity (by 1,000- to 10,000-fold).
Activated AT-III irreversibly inhibits thrombin (Factor IIa), Factor Xa, and to lesser extents Factors IXa, XIa, and XIIa.
Unfractionated heparin (UFH) inhibits both thrombin and Factor Xa equally (requires 18-unit chain to bridge AT-III and thrombin simultaneously).

Features:

Cannot cross the placenta → safe in pregnancy (drug of choice for anticoagulation during pregnancy).
Does not cross into breast milk.
Administered intravenously (continuous infusion) or subcutaneously. NOT orally bioavailable.
Monitored using activated partial thromboplastin time (aPTT); target 1.5-2.5x control.
Antidote: Protamine sulfate (positively charged protein that neutralizes heparin by ionic binding).

Indications: Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), acute coronary syndromes, prevention of clotting during cardiac surgery and hemodialysis, bridging anticoagulation perioperatively.

Side Effects:

Bleeding (primary risk - major hemorrhage).
Heparin-Induced Thrombocytopenia (HIT): Type I (non-immune, mild, transient platelet fall); Type II (immune-mediated - IgG antibodies form against heparin-PF4 complexes, causing platelet activation, thrombocytopenia, and paradoxically a hypercoagulable state with arterial and venous thrombosis). HIT II requires immediate heparin discontinuation and substitution with a direct thrombin inhibitor (argatroban).
Osteoporosis (long-term use - inhibits osteoblast function).
Hypersensitivity reactions, elevated liver transaminases.

Direct Thrombin Inhibitors (DTIs)

Parenteral DTIs: Argatroban (hepatically cleared - use in HIT and renal failure), bivalirudin (used in PCI), lepirudin (renally cleared - now rarely used).
Oral DTIs: Dabigatran etexilate.
Mechanism: Bind directly to the active site of thrombin (Factor IIa), inhibiting its activity without requiring AT-III as a cofactor. They inhibit both free thrombin and clot-bound thrombin (advantage over heparin, which cannot inhibit clot-bound thrombin).
Dabigatran: Oral prodrug converted to dabigatran. Renally excreted. Used for stroke prevention in non-valvular atrial fibrillation, DVT/PE treatment. Antidote: Idarucizumab (specific monoclonal antibody fragment).

Direct Factor Xa Inhibitors

Oral: Rivaroxaban, apixaban, edoxaban.
Parenteral: Fondaparinux (synthetic pentasaccharide; AT-III-dependent Xa inhibitor).
Mechanism: Directly inhibit Factor Xa, blocking the conversion of prothrombin to thrombin. They act on both free Xa and Xa within the prothrombinase complex.
Features: Predictable pharmacokinetics, no routine monitoring required. Antidote for rivaroxaban/apixaban: Andexanet alfa (recombinant modified Factor Xa that acts as a decoy). Fondaparinux antidote: No specific antidote; protamine is ineffective.
Indications: Stroke prevention in non-valvular atrial fibrillation, treatment and prevention of DVT/PE, post-orthopedic surgery thromboprophylaxis.

21. Low Molecular Weight Heparins (LMWHs)

LMWHs are derived from standard unfractionated heparin by chemical or enzymatic depolymerization, producing fragments with molecular weights of 1,000-10,000 Da (mean ~5,000 Da).

Mechanisms and Features of Action

Mechanism: Like UFH, LMWHs (enoxaparin, dalteparin, nadroparin, tinzaparin) act via antithrombin III (AT-III). However, due to their smaller chain length, LMWHs preferentially inhibit Factor Xa over thrombin in a ratio of approximately 2:1 to 4:1 (compared to 1:1 for UFH). The shorter chains cannot simultaneously bridge AT-III and thrombin, so anti-IIa activity is reduced.

Pharmacokinetic Advantages over UFH:

More predictable dose-response relationship due to less non-specific protein binding.
Higher and more consistent bioavailability (>90% after subcutaneous injection vs. ~30% for UFH).
Longer half-life (4-6 hours vs. 1-2 hours for UFH) → once or twice daily subcutaneous dosing.
No routine aPTT monitoring required (can monitor anti-Xa levels in special populations: renal impairment, obesity, pregnancy).
Lower risk of HIT Type II compared to UFH.
Partial reversal with protamine sulfate (neutralizes anti-IIa but not anti-Xa activity).

Indications

Prevention of DVT and PE (thromboprophylaxis) in hospitalized medical and surgical patients, orthopedic surgery (hip and knee replacement).
Treatment of established DVT and PE.
Treatment of acute coronary syndromes (unstable angina, NSTEMI).
Anticoagulation during pregnancy (drug of choice along with UFH - does not cross placenta).
Bridging anticoagulation for patients on warfarin undergoing invasive procedures.

Side Effects

Bleeding (less than UFH at equivalent antithrombotic doses).
HIT Type II (less frequent than UFH but possible - requires same management).
Osteoporosis (less than UFH with long-term use).
Injection-site hematoma and bruising.
Accumulation in renal failure (renally cleared) → increased bleeding risk. Dose reduction or switch to UFH required in severe renal impairment (CrCl <30 mL/min).

22. Warfarin

Warfarin is an oral anticoagulant of the coumarin class, acting as a vitamin K antagonist.

Mechanisms and Features of Action

Mechanism: Warfarin competitively inhibits vitamin K epoxide reductase complex 1 (VKORC1), the enzyme responsible for recycling oxidized vitamin K (vitamin K epoxide) back to its reduced, active form (vitamin K hydroquinone). Active vitamin K hydroquinone is required as a cofactor for the carboxylation of glutamic acid residues on the vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins (Protein C, Protein S). Without carboxylation, these factors cannot bind calcium and are functionally inactive.

Features:

Oral administration with excellent bioavailability.
Onset of action is delayed 2-3 days (existing activated clotting factors must first be consumed; Factor VII has the shortest half-life and falls first - reflected in a rising INR).
Full anticoagulant effect takes 5-7 days.
Monitored using Prothrombin Time (PT) expressed as the International Normalized Ratio (INR). Target INR is 2.0-3.0 for most indications (2.5-3.5 for mechanical heart valves).
Highly protein-bound (99% to albumin) → numerous drug interactions (drugs that displace warfarin from albumin or affect CYP2C9 alter its effect).
Crosses the placenta → Teratogenic (warfarin embryopathy: nasal hypoplasia, bone stippling); contraindicated in first and third trimesters of pregnancy.
Antidote: Vitamin K₁ (phytonadione) - slow reversal (12-24 hours). For urgent reversal: Four-factor Prothrombin Complex Concentrate (4F-PCC) or Fresh Frozen Plasma (FFP).

Drug Interactions:

Drugs that increase warfarin effect (bleeding risk): CYP2C9 inhibitors (amiodarone, fluconazole, metronidazole), aspirin, broad-spectrum antibiotics (reduce gut flora vitamin K production).
Drugs that decrease warfarin effect (clotting risk): CYP2C9 inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort), vitamin K-rich foods (green leafy vegetables).

Indications

Prevention of stroke and systemic embolism in atrial fibrillation (especially valvular AF or when DOACs are contraindicated).
Treatment and secondary prevention of DVT and PE.
Prevention of thromboembolism in patients with mechanical prosthetic heart valves (warfarin is the only anticoagulant approved for mechanical valves).
Antiphospholipid syndrome with recurrent thrombosis.

Side Effects

Bleeding (the primary and most dangerous complication - from minor bruising to life-threatening intracranial hemorrhage).
Warfarin skin necrosis: Rare; occurs 3-5 days after initiation in patients with Protein C or Protein S deficiency (Protein C has the shortest half-life after VKORC1 inhibition begins, creating a transient hypercoagulable state).
Teratogenicity: Warfarin embryopathy (weeks 6-12), fetal hemorrhage (third trimester).
Purple toe syndrome: Rare; cholesterol microemboli released by anticoagulation-related dissolution of cholesterol plaques.
Drug-drug and drug-food interactions (extremely common - INR must be monitored closely with any medication change).

23. Thrombolytic Drugs

Thrombolytics (fibrinolytics) are agents that dissolve existing thrombi by activating the endogenous fibrinolytic system.

Mechanisms of Action

Core Mechanism: All thrombolytics directly or indirectly activate plasminogen → convert it to plasmin → plasmin cleaves fibrin within thrombi → clot dissolution. Plasmin also degrades fibrinogen, Factor V, and Factor VIII (causing a systemic lytic state).

Streptokinase: A bacterial protein (from beta-hemolytic streptococci) that forms a 1:1 complex with plasminogen. This complex then activates other plasminogen molecules. Non-fibrin-selective (activates systemic plasminogen, causing a systemic lytic state). Antigenic - can cause hypersensitivity reactions and resistance on re-exposure.

Alteplase (rt-PA - recombinant tissue plasminogen activator): Recombinant human tPA that binds to fibrin within thrombi, preferentially activating fibrin-bound plasminogen. Relatively fibrin-selective (reduces systemic bleeding compared to streptokinase). Short half-life (~5 minutes) requiring continuous IV infusion.

Tenecteplase (TNK-tPA): Engineered variant of alteplase with longer half-life (allowing single IV bolus), greater fibrin selectivity, and resistance to plasminogen activator inhibitor-1 (PAI-1). More convenient administration.

Reteplase (r-PA): Modified tPA; slightly less fibrin-selective than alteplase but longer half-life allowing double-bolus administration.

Urokinase: Human serine protease directly converts plasminogen to plasmin. Non-fibrin-selective. Used primarily for catheter-directed thrombolysis and clearing occluded catheters.

Therapeutic Use

Acute ST-Elevation Myocardial Infarction (STEMI): When primary PCI is not available within the recommended time window (door-to-balloon time >120 minutes). Alteplase, tenecteplase, or reteplase are preferred over streptokinase.
Massive Pulmonary Embolism with hemodynamic instability (hypotension, cardiac arrest).
Acute Ischemic Stroke: Alteplase (or tenecteplase) administered within 4.5 hours of symptom onset in eligible patients.
Massive DVT with limb-threatening ischemia (catheter-directed thrombolysis).
Occluded central venous catheters (low-dose urokinase or alteplase).

Adverse Effects

Bleeding (the dominant and most serious complication): Intracranial hemorrhage (most feared - approximately 0.9-1% with alteplase for stroke), major systemic hemorrhage, hemorrhagic transformation of ischemic stroke.
Allergic reactions: Hypersensitivity, fever, and anaphylaxis with streptokinase (due to its bacterial origin).
Reperfusion arrhythmias: After coronary thrombolysis as the occluded vessel reopens (usually transient and self-limiting).
Hypotension: Especially with streptokinase (bradykinin release).

Absolute Contraindications: Prior intracranial hemorrhage, active internal bleeding, recent intracranial surgery or trauma, known intracranial neoplasm, arteriovenous malformation, uncontrolled severe hypertension.

24. Fibrinolytic Agents

(Note: Fibrinolytic agents and thrombolytic drugs overlap significantly. This section focuses on classification distinctions and specific clinical nuances.)

Classification

First-Generation (Non-Fibrin-Selective):

Streptokinase, urokinase.
Activate circulating (systemic) plasminogen indiscriminately → marked systemic fibrinogenolysis → high bleeding risk.

Second-Generation (Fibrin-Selective):

Alteplase (rt-PA).
Preferentially activates plasminogen bound to fibrin within a thrombus → more targeted clot dissolution with somewhat less systemic fibrinogenolysis.

Third-Generation (Enhanced Fibrin-Selectivity and Pharmacokinetics):

Tenecteplase, reteplase, desmoteplase (experimental).
Engineered for improved fibrin selectivity, resistance to PAI-1, and longer half-lives enabling bolus dosing.

Endogenous Fibrinolysis Modulators:

Tranexamic acid and epsilon-aminocaproic acid are antifibrinolytics (not fibrinolytics) that inhibit plasminogen activation by blocking lysine-binding sites, used to control bleeding.

Mechanisms of Action

All fibrinolytic agents ultimately produce plasmin from plasminogen. Plasmin:

Cleaves fibrin → degrades the structural backbone of the clot.
Degrades fibrinogen, Factor V, and Factor VIII.
Produces fibrin degradation products (FDPs) and D-dimers (clinical markers of fibrinolysis).

Clinical Use

Same as thrombolytics above (STEMI, massive PE, acute ischemic stroke, massive DVT).

Catheter-Directed Thrombolysis (CDT): Low-dose fibrinolytics (alteplase, urokinase) infused directly into a thrombus via catheter → higher local concentration with lower systemic dose → reduced bleeding risk compared to systemic administration. Used for sub-massive PE, iliofemoral DVT, peripheral arterial occlusion.

Side Effects

Same as thrombolytics above. The most clinically relevant differentiator:

Streptokinase: Antigenic reactions, hypotension, cannot be re-used within 6 months to 1 year (neutralizing antibodies).
Alteplase/Tenecteplase: More expensive, no antigenicity, preferred in STEMI and stroke.

25. Iron Drugs: Metabolism, Classification, Mechanisms, Clinical Use, Side Effects

Metabolism of Iron

Absorption: Dietary iron is absorbed in the duodenum and upper jejunum. Ferric iron (Fe³⁺) must first be reduced to ferrous iron (Fe²⁺) by duodenal cytochrome B (DcytB) on the brush border. Fe²⁺ is then transported into the enterocyte via the Divalent Metal Transporter 1 (DMT-1). Inside the enterocyte, iron is either stored as ferritin or exported into the bloodstream via ferroportin.

Plasma Transport: Iron is exported as Fe²⁺, oxidized back to Fe³⁺ by hephaestin (at the enterocyte) or ceruloplasmin (in plasma), and bound to transferrin (one transferrin molecule carries two Fe³⁺ ions) for transport.

Cellular Uptake: Transferrin-Fe³⁺ complexes bind to transferrin receptors (TfR1) on target cells (erythroid precursors, hepatocytes) → endocytosis → Fe³⁺ released in acidic endosome → reduced to Fe²⁺ by STEAP3 → exported to cytoplasm via DMT-1.

Storage: Stored as ferritin (soluble, non-toxic, short-term store) or hemosiderin (insoluble, long-term store) in liver, spleen, and bone marrow.

Regulation: Hepcidin (a hepatic peptide hormone) is the master regulator of iron homeostasis. Hepcidin binds ferroportin → causes its internalization and degradation → blocks iron export from enterocytes, macrophages, and hepatocytes → reduces plasma iron. Inflammation markedly increases hepcidin (explaining anemia of chronic disease - iron is trapped in stores).

Excretion: Humans have no regulated iron excretion pathway. Iron is lost passively through shedding of intestinal epithelial cells, skin desquamation, and minor blood loss (menstruation). This makes iron overload a significant clinical problem.

Classification

Oral Iron Preparations:

Ferrous sulfate (most commonly used), ferrous gluconate, ferrous fumarate, ferrous succinate.
These are Fe²⁺ salts, directly absorbable by DMT-1.

Parenteral Iron Preparations:

Iron sucrose (Venofer), ferric carboxymaltose (Ferinject), low molecular weight iron dextran, ferumoxytol, sodium ferric gluconate (Ferrlecit).
Used when oral iron is not tolerated, not absorbed, or insufficient (e.g., inflammatory bowel disease, chronic kidney disease on dialysis, heart failure with iron deficiency).

Mechanisms of Action

Oral and parenteral iron preparations replenish depleted iron stores, correcting iron deficiency. Restored iron is incorporated into hemoglobin (heme synthesis in erythroid precursors), myoglobin, cytochromes, and iron-containing enzymes.

Clinical Use

Iron deficiency anemia (the most common nutritional deficiency worldwide): Caused by insufficient dietary intake, malabsorption (celiac disease, post-gastrectomy), chronic blood loss (heavy menstruation, GI bleeding), or increased demand (pregnancy).
Ferrous sulfate is the standard first-line oral agent. Taken on an empty stomach with vitamin C (ascorbic acid reduces Fe³⁺ to Fe²⁺ and acidifies the environment, enhancing absorption). Take 30-60 minutes before meals.
Parenteral iron: Reserved for patients intolerant to oral iron, non-compliant, with malabsorption syndromes, or requiring rapid iron repletion (e.g., pre-operative anemia, stage 3-5 CKD, heart failure).
Reticulocyte count rises within 3-5 days and hemoglobin begins to rise by 1-2 weeks. Continue treatment for 3-6 months after hemoglobin normalization to replenish stores.

Side Effects

Oral Iron:

Gastrointestinal: Nausea, epigastric discomfort, constipation (most common), diarrhea. Black, tarry stools (harmless, due to unabsorbed iron - but can mask GI bleeding).
Compliance is often poor due to GI intolerance. Taking iron with food reduces GI side effects but decreases absorption.

Parenteral Iron:

Anaphylaxis and serious hypersensitivity reactions (especially with high-molecular-weight iron dextran - rare but potentially fatal; test dose historically required; lower risk with iron sucrose and ferric carboxymaltose).
Hypotension, flushing, chest tightness (infusion reactions).
Arthralgia and myalgia (delayed, 24-48 hours post-infusion).
Iron overload (hemosiderosis, hemochromatosis) with excessive dosing.

Iron Overdose (Acute Toxicity in Children):

A leading cause of accidental poisoning deaths in young children.
Stages: Nausea/vomiting/diarrhea (0-6 hours) → apparent recovery (6-24 hours) → metabolic acidosis, hepatotoxicity, coagulopathy, shock (24-48 hours) → late complications: pyloric stenosis, hepatic cirrhosis.
Treatment: Gastric lavage, deferoxamine (specific chelating agent, forms ferrioxamine excreted by kidneys).

26. Cyanocobalamin (Vitamin B₁₂): Oral Metabolism, Clinical Uses, Side Effects

Oral Metabolism

Dietary Sources: Vitamin B₁₂ (cyanocobalamin and its analogues - hydroxocobalamin, methylcobalamin, adenosylcobalamin) is found exclusively in animal products (meat, fish, dairy, eggs). Strict vegans are at risk for deficiency.

Gastric Phase: In the stomach, pepsin and gastric acid cleave B₁₂ from food proteins. The freed B₁₂ then binds to R-protein (haptocorrin), a binding protein secreted by salivary glands and the gastric mucosa. Parietal cells of the gastric fundus simultaneously secrete Intrinsic Factor (IF), a glycoprotein essential for B₁₂ absorption.

Duodenal Phase: Pancreatic proteases degrade the R-protein-B₁₂ complex in the duodenum, releasing free B₁₂. Free B₁₂ then binds to Intrinsic Factor (IF), forming the IF-B₁₂ complex.

Ileal Absorption: The IF-B₁₂ complex travels to the terminal ileum, where it binds to specific cubilin receptors on ileal enterocytes → receptor-mediated endocytosis → B₁₂ is released from IF within the enterocyte → enters the portal circulation bound to transcobalamin II (the major transport protein).

Hepatic Storage: The liver stores enormous amounts of B₁₂ (2,000-5,000 μg; 3-5 years supply). This explains why dietary deficiency takes years to manifest clinically.

Causes of Deficiency:

Pernicious anemia: Autoimmune destruction of gastric parietal cells → absence of Intrinsic Factor → impaired ileal absorption (most common cause in developed countries).
Gastric surgery (gastrectomy), atrophic gastritis → reduced IF production.
Terminal ileum disease/resection (Crohn's disease, ileal resection) → loss of absorption site.
Strict veganism (dietary deficiency).
Long-term metformin use → reduces IF-B₁₂ complex uptake (mechanism unclear).
Long-term PPI use → reduces protein-bound B₁₂ release from food.

Note on Passive Absorption: A small fraction (1-2%) of oral B₁₂ is absorbed by passive diffusion throughout the small intestine, independent of Intrinsic Factor. This is the basis for high-dose oral B₁₂ replacement (1,000-2,000 μg/day orally) even in pernicious anemia.

Clinical Uses

Biochemical Roles:

Methylcobalamin is required for methionine synthase, which converts homocysteine to methionine using methyltetrahydrofolate (methyl-THF) as the methyl donor. Without B₁₂, methyl-THF is trapped (the "folate trap") → THF cannot be regenerated → impaired DNA synthesis (megaloblastic anemia).
Adenosylcobalamin is required for methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA. Deficiency → methylmalonic acid (MMA) accumulates → neurotoxicity.

Indications:

Megaloblastic (macrocytic) anemia due to B₁₂ deficiency.
Pernicious anemia (requires parenteral B₁₂ or high-dose oral if IF is absent).
Subacute combined degeneration of the spinal cord (posterior column degeneration causing sensory ataxia, and lateral column degeneration causing upper motor neuron signs; caused by MMA accumulation and impaired myelin synthesis).
Prevention of B₁₂ deficiency in at-risk populations (vegans, post-gastrectomy, elderly, long-term metformin/PPI users).

Formulations:

Cyanocobalamin: Synthetic, most stable, converted to active forms in the body.
Hydroxocobalamin: Natural form, longer-acting, preferred in the UK. Also the antidote for cyanide poisoning (cyanide displaces CN⁻ from cyanocobalamin to form non-toxic cyanocobalamin-CN, i.e., just cyanocobalamin).
Methylcobalamin/Adenosylcobalamin: Active forms, used in some countries.

Routes of Administration:

Intramuscular (IM) injection: Standard for pernicious anemia (hydroxocobalamin 1,000 μg IM every 2-3 months after loading doses).
Oral high-dose: Effective even in pernicious anemia via passive absorption (1,000-2,000 μg/day).
Intranasal: Available for maintenance therapy.

Side Effects

Vitamin B₁₂ is generally extremely safe even at very high doses (water-soluble; excess excreted in urine).

Rarely: Mild diarrhea, skin rash, itching.
Hydroxocobalamin IM: Injection-site pain, local reactions.
Hypokalemia: Can occur during initial treatment of severe megaloblastic anemia as rapid erythropoiesis consumes potassium (monitor electrolytes).
Masking of folate deficiency: Treating B₁₂ deficiency can improve anemia but neurological damage due to B₁₂ deficiency can worsen if folate is given without B₁₂ in pernicious anemia.
Drug interactions: No significant pharmacokinetic interactions, but metformin, PPIs, and H₂RAs reduce B₁₂ absorption with long-term use.

27. Drugs for Diabetes Mellitus Type 1: Insulin and Insulin Analogues

Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of pancreatic beta cells → absolute insulin deficiency → requires exogenous insulin for survival.

Insulin: Structure and Mechanism

Structure: Insulin is a polypeptide hormone consisting of an A-chain (21 amino acids) and a B-chain (30 amino acids) connected by two disulfide bonds.

Mechanism of Action: Insulin binds to the insulin receptor (a transmembrane tyrosine kinase receptor) on target cells (muscle, adipose tissue, liver). Receptor autophosphorylation → activation of the IRS-1/PI3K/Akt signaling cascade → multiple metabolic effects:

Glucose transport: Stimulates GLUT-4 translocation to the cell membrane in muscle and adipose tissue → increased glucose uptake.
Glycogen synthesis: Activates glycogen synthase → promotes glycogenesis in liver and muscle.
Lipid metabolism: Stimulates lipogenesis, inhibits lipolysis in adipose tissue.
Protein synthesis: Promotes amino acid uptake and protein synthesis.
Anti-catabolism: Inhibits gluconeogenesis, glycogenolysis, ketogenesis, and proteolysis.

Classification by Duration of Action

Type	Examples	Onset	Peak	Duration
Rapid-Acting Analogues	Insulin lispro, aspart, glulisine	5-15 min	30-90 min	3-5 hours
Short-Acting (Regular Insulin)	Neutral/regular insulin (Actrapid)	30-60 min	2-3 hours	5-8 hours
Intermediate-Acting	NPH insulin (Isophane)	1-2 hours	4-8 hours	12-18 hours
Long-Acting Analogues	Insulin glargine, detemir	1-2 hours	Flat (no peak)	20-24 hours
Ultra-Long-Acting Analogues	Insulin degludec	30-90 min	Flat	>42 hours
Premixed Insulins	70/30 (NPH/Regular), BiAsp 30	Variable	Biphasic	Variable

Rapid-Acting Analogues (Lispro, Aspart, Glulisine):

Engineered by substituting or reversing amino acids in the B-chain to reduce self-association (these analogues exist as monomers rather than hexamers at injection site) → faster absorption.
Lispro: B28 lysine and B29 proline positions are reversed.
Aspart: B28 proline replaced by aspartate.
Administered immediately before meals or even post-meal in unpredictable eating situations (children, elderly).

Long-Acting Analogues (Glargine, Detemir):

Glargine: Point mutation (Asn→Gly at A21) + addition of two arginines to B-chain. Forms microprecipitates at physiological pH subcutaneous tissue → slow, peakless absorption.
Detemir: B30 threonine deleted + B29 lysine acylated with a C14 fatty acid → binds albumin at injection site and in plasma → prolonged and buffered release.
Provide basal insulin coverage (mimic the low constant insulin secretion of normal beta cells overnight and between meals).

Insulin Regimens in T1DM

Basal-Bolus Regimen (Gold Standard):

One or two daily injections of long-acting insulin (glargine or detemir) → covers basal requirements.
Rapid-acting insulin (lispro, aspart) before each meal → covers postprandial glucose excursions.
Most physiological approach; best HbA1c control with lowest hypoglycemia risk when properly managed.

Continuous Subcutaneous Insulin Infusion (CSII - Insulin Pump):

Delivers rapid-acting insulin continuously via a subcutaneous catheter.
Programmable basal rates and bolus doses.
Best HbA1c control and quality of life in motivated patients.

Premixed Regimens:

Two injections daily (before breakfast and before dinner).
Less flexible; more hypoglycemia risk; used in T2DM more than T1DM.

Side Effects of Insulin

Hypoglycemia (the primary and most dangerous complication): From mild (sweating, tremor, palpitations - adrenergic symptoms) to severe (confusion, seizures, coma - neuroglycopenic symptoms). Risk factors: missed meals, excess insulin dose, exercise, alcohol, renal failure.
Weight gain (insulin is anabolic - promotes fat and glycogen storage).
Injection-site lipohypertrophy (from repeated injections at the same site → erratic insulin absorption - prevent by rotating injection sites).
Lipodystrophy and local allergic reactions at injection site (rare with modern human insulin and analogues).
Hypokalemia (insulin drives K⁺ into cells via Na⁺/K⁺-ATPase activation - clinically used to treat hyperkalemia).
Edema (insulin causes renal sodium retention, especially at treatment initiation in poorly controlled diabetes).

28. Drugs for Diabetes Mellitus Type 2: Classification, Mechanisms, Adverse Effects

Type 2 diabetes mellitus (T2DM) is characterized by a combination of peripheral insulin resistance and progressive beta-cell dysfunction. Treatment targets these pathophysiological defects.

Classification and Mechanisms of Action

Biguanides:

Metformin (the cornerstone first-line agent in T2DM).
Mechanism: Activates AMP-activated protein kinase (AMPK) in the liver → inhibits mitochondrial Complex I of the respiratory chain → increases AMP:ATP ratio → activates AMPK → inhibits gluconeogenesis (primary mechanism) and glycogenolysis → reduces fasting hepatic glucose output. Also improves peripheral insulin sensitivity.
Features: Does not cause hypoglycemia (does not stimulate insulin secretion). Does not cause weight gain (weight-neutral to mildly weight-reducing). Reduces cardiovascular events (UKPDS trial evidence). Renally excreted.
Adverse Effects: Gastrointestinal (nausea, diarrhea, abdominal discomfort - take with food; usually transient). Lactic acidosis (rare but potentially fatal; risk increases with renal impairment, liver disease, cardiac failure, sepsis, contrast media use - hold metformin before iodinated contrast). Long-term use reduces vitamin B₁₂ absorption. Contraindicated in eGFR <30 mL/min.

Sulfonylureas:

Glibenclamide (glyburide), glipizide, gliclazide, glimepiride (second-generation); tolbutamide, chlorpropamide (first-generation, largely obsolete).
Mechanism: Bind to and close ATP-sensitive K⁺ (K_ATP) channels on pancreatic beta-cell membranes → membrane depolarization → voltage-gated Ca²⁺ channels open → Ca²⁺ influx → insulin exocytosis. Act independently of blood glucose levels.
Features: Effective glucose-lowering agents; inexpensive. Stimulate insulin secretion regardless of glucose → hypoglycemia risk.
Adverse Effects: Hypoglycemia (major concern, especially in the elderly and with renal impairment; glibenclamide has the highest risk due to its active metabolites). Weight gain (insulin release promotes fat storage). Rare: cholestatic jaundice, hematological reactions.

Meglitinides (Glinides):

Repaglinide, nateglinide.
Mechanism: Same K_ATP channel target as sulfonylureas but bind at a different site. Rapid onset and short duration → stimulate meal-time insulin secretion (prandial insulin secretagogues).
Features: Taken only with meals; skip dose if skipping a meal. Less hypoglycemia risk than sulfonylureas (shorter action). Primarily metabolized hepatically (can be used in mild-moderate renal impairment).
Adverse Effects: Hypoglycemia (less than sulfonylureas), weight gain.

Thiazolidinediones (Glitazones) - PPARγ Agonists:

Pioglitazone, rosiglitazone.
Mechanism: Activate peroxisome proliferator-activated receptor gamma (PPARγ) in adipose tissue and muscle → regulate gene expression of glucose transporters (GLUT-4), fatty acid metabolism enzymes, and adipokines (adiponectin) → improve peripheral insulin sensitivity. Increase glucose uptake and utilization in muscle and adipose tissue; reduce free fatty acid release.
Features: Do not cause hypoglycemia (no direct insulin secretion). Slow onset (weeks to months for full effect). Pioglitazone reduces triglycerides and raises HDL.
Adverse Effects: Fluid retention and edema (PPARγ activation causes renal Na⁺ reabsorption - contraindicated in heart failure). Weight gain (redistribution of fat to subcutaneous depots). Bone fractures (increased risk in women - PPARγ activation suppresses osteoblast differentiation). Rosiglitazone: increased risk of myocardial infarction (substantially restricted in many countries). Pioglitazone: possible increased risk of bladder cancer with long-term use.

DPP-4 Inhibitors (Gliptins):

Sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin.
Mechanism: Inhibit dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly degrades incretins (GLP-1 and GIP). By blocking DPP-4, GLP-1 and GIP levels increase 2-3-fold. Elevated GLP-1 → stimulates glucose-dependent insulin secretion from beta-cells → suppresses glucagon secretion from alpha-cells. Because the effect is glucose-dependent, hypoglycemia is rare.
Features: Weight-neutral. Oral, once-daily (mostly). Well tolerated.
Adverse Effects: Nasopharyngitis, upper respiratory tract infections, urinary tract infections. Rare: acute pancreatitis (controversial causal link). Saxagliptin/alogliptin: increased hospitalization for heart failure (FDA warning - mechanism unclear).

GLP-1 Receptor Agonists:

Short-acting: Exenatide (twice daily), liraglutide (once daily).
Long-acting/weekly: Semaglutide, dulaglutide, exenatide extended-release.
Mechanism: Synthetic GLP-1 analogues resistant to DPP-4 degradation. Bind GLP-1 receptors → glucose-dependent insulin secretion → suppression of glucagon → slowed gastric emptying (reduces postprandial glucose excursions) → central appetite suppression (hypothalamic GLP-1 receptors) → significant weight loss. Also reduce cardiovascular events (LEADER, SUSTAIN-6 trials - liraglutide and semaglutide reduce MACE in T2DM with established CVD).
Features: Subcutaneous injection (except oral semaglutide). Significant weight loss (5-10% body weight). Cardiovascular and renal protective effects.
Adverse Effects: Nausea, vomiting, diarrhea (dose-dependent, usually transient - the "GLP-1 GI side effect"); hypoglycemia (rare as monotherapy - glucose-dependent). Injection-site reactions. Acute pancreatitis (rare, black box warning). Thyroid C-cell tumors in rodents (medullary thyroid carcinoma risk - contraindicated in MEN2 and personal/family history of medullary thyroid carcinoma). Gallstones (rapid weight loss).

SGLT-2 Inhibitors (Gliflozins):

Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin.
Mechanism: Inhibit sodium-glucose cotransporter 2 (SGLT-2) in the proximal convoluted tubule of the kidney. SGLT-2 is responsible for reabsorbing ~90% of filtered glucose. Blocking it → glucosuria (spill ~60-100g of glucose into urine daily regardless of insulin levels) → lowers blood glucose. Also cause natriuresis → reduce blood pressure and blood volume (preload reduction - beneficial in heart failure).
Features: Insulin-independent mechanism → effective even with low beta-cell function. Significant weight loss (calorie loss through urine). Blood pressure reduction. Profound cardiovascular benefits (reduce hospitalization for heart failure, reduce progression of diabetic nephropathy - EMPA-REG, CANVAS, DECLARE trials). Now indicated for heart failure with reduced ejection fraction regardless of T2DM status.
Adverse Effects: Urogenital infections - genital mycotic infections (candidiasis, especially in women) and urinary tract infections (most common side effect, due to glucosuria creating a substrate for fungal/bacterial growth). Euglycemic diabetic ketoacidosis (rare but serious - DKA with near-normal blood glucose, can occur under stress, surgery, very low-carbohydrate diet; mechanism: relative insulin deficiency + SGLT-2-mediated volume depletion → ketogenesis). Fournier's gangrene (necrotizing fasciitis of the perineum - rare). Polyuria, volume depletion, hypotension (caution in elderly). Canagliflozin: increased risk of lower limb amputations and bone fractures (exact mechanism unclear - FDA black box warning for canagliflozin specifically). Hyperkalemia (modest).

Alpha-Glucosidase Inhibitors:

Acarbose, miglitol, voglibose.
Mechanism: Competitive inhibition of alpha-glucosidase enzymes (maltase, glucoamylase, sucrase) at the intestinal brush border → delays digestion and absorption of complex carbohydrates and disaccharides → blunts postprandial glucose excursions. No effect on fasting glucose.
Features: Must be taken with the first bite of each meal. No systemic absorption (act locally in the gut). No hypoglycemia as monotherapy. Modest glucose-lowering efficacy.
Adverse Effects: Flatulence, bloating, diarrhea, abdominal cramping (undigested carbohydrates fermented by colonic bacteria - dose-dependent, the major limitation of this class). Rare: elevated liver transaminases (acarbose, at high doses).

Insulin (in T2DM):

Used when oral agents fail to achieve glycemic targets or in specific situations (acute illness, surgery, pregnancy, severe hyperglycemia with symptoms).
Same types and mechanisms as in T1DM.
Often started as basal insulin (glargine or detemir) added to oral agents, then intensified to basal-bolus as needed.

---All 28 questions are now answered in full, following the same structured format as the previous response - bold subheadings, consistent section headers (Classification and Mechanisms, Indications, Side Effects, etc.), bullet points for drug lists, tables where comparison is useful, and plain descriptive prose for mechanisms. Here is a quick summary of what was covered in questions 12-28:

#	Topic	Key Drug Examples
12	Potassium-sparing diuretics	Spironolactone, eplerenone, amiloride, triamterene
13	ACE inhibitors	Enalapril, lisinopril, ramipril, captopril
14	AT₁-receptor blockers	Losartan, valsartan, candesartan
15	Antiemetic agents	Ondansetron, metoclopramide, aprepitant, scopolamine
16	Drugs reducing gastric acidity	Omeprazole, ranitidine, sucralfate, misoprostol
17	Laxatives	Lactulose, bisacodyl, psyllium, PEG, docusate
18	Drugs affecting the uterus	Oxytocin, ergometrine, misoprostol, nifedipine, atosiban
19	Antiplatelet agents	Aspirin, clopidogrel, ticagrelor, GP IIb/IIIa blockers
20	Heparin + Direct Xa/IIa inhibitors	UFH, dabigatran, rivaroxaban, apixaban
21	LMWHs	Enoxaparin, dalteparin, nadroparin
22	Warfarin	Coumarin; VKORC1 inhibition; INR monitoring
23	Thrombolytics	Alteplase, tenecteplase, streptokinase
24	Fibrinolytic agents	Generations 1-3; catheter-directed thrombolysis
25	Iron drugs	Ferrous sulfate, parenteral iron; full iron metabolism
26	Cyanocobalamin (B₁₂)	Intrinsic factor pathway; hydroxocobalamin; pernicious anemia
27	Insulin and analogues (T1DM)	Glargine, lispro, aspart, degludec; basal-bolus regimen
28	T2DM drugs	Metformin, sulfonylureas, GLP-1 agonists, SGLT-2 inhibitors, glitazones, DPP-4 inhibitors

Can you remove/cut unnecessary paragraphs, word and explanation by rewriting it. Make it more exam oriented.

Here is the fully rewritten, exam-focused version of all 28 questions.

1. Antitussives and Expectorants

Classification and Mechanisms

Central Antitussives (Opioids): Codeine, dextromethorphan - suppress the cough center in the medulla oblongata.

Peripheral Antitussives: Prenoxdiazine, levodropropizine - reduce sensitivity of respiratory tract stretch receptors.

Secretomotor Expectorants: Ammonium chloride, potassium iodide - irritate gastric mucosa to reflexively increase bronchial secretions.

Mucolytics: N-acetylcysteine (breaks disulfide bonds in mucoproteins), ambroxol (stimulates surfactant production), bromhexine.

Indications

Antitussives: Dry, non-productive cough (post-viral, lung cancer).
Expectorants/Mucolytics: Productive cough with thick sputum (bronchitis, COPD, cystic fibrosis).

Side Effects

Opioid antitussives: Sedation, constipation, respiratory depression, addiction.
Expectorants/Mucolytics: GI irritation, nausea, bronchospasm (inhaled mucolytics in asthmatics).

2. Bronchodilators

Classification and Mechanisms

β₂-Adrenergic Agonists:

SABA: Salbutamol, albuterol.
LABA: Salmeterol, formoterol.
Mechanism: β₂ stimulation → ↑cAMP → smooth muscle relaxation.

Anticholinergics:

SAMA: Ipratropium bromide.
LAMA: Tiotropium bromide.
Mechanism: Block M₃ receptors → inhibit vagal bronchoconstriction and mucus secretion.

Methylxanthines: Theophylline, aminophylline - inhibit PDE (↑cAMP) and block adenosine receptors.

Treatment of Asthma and Broncho-Obstructive Syndromes

Acute asthma: SABA (salbutamol) first-line rescue + SAMA (ipratropium).
Chronic asthma maintenance: LABA (salmeterol/formoterol) always paired with ICS.
COPD: LAMA + LABA as foundational maintenance therapy.

Side Effects

β₂-Agonists: Tremors, tachycardia, palpitations, hypokalemia.
Anticholinergics: Dry mouth, urinary retention, blurred vision, constipation.
Methylxanthines: Narrow therapeutic window - insomnia, arrhythmias, seizures, vomiting.

3. Cardiac Glycosides

Mechanisms of Action

Inhibition of Na⁺/K⁺-ATPase: Digoxin inhibits the pump → ↑intracellular Na⁺ → slows Na⁺/Ca²⁺ exchanger → ↑intracellular Ca²⁺ → enhanced contractility (positive inotropy).

Heart Rate and Conduction: Increases vagal tone → slows SA node (negative chronotropy) → prolongs AV node conduction (negative dromotropy).

Hemodynamics: ↑cardiac output → ↓LVEDP, ↓systemic vascular resistance.

Renal Function: ↑cardiac output → ↑renal perfusion → promotes diuresis → ↓RAAS activation.

Indications

Chronic HFrEF symptomatic despite optimal therapy.
Ventricular rate control in atrial fibrillation/flutter.

4. Glycoside Intoxication (Digitalis Toxicity)

Narrow therapeutic index: 0.5-2.0 ng/mL.

Pathogenesis

Excessive intracellular Ca²⁺ overload + severe Na⁺/K⁺-ATPase inhibition. Hypokalemia worsens toxicity (K⁺ competes with digoxin at pump binding site). Hypomagnesemia and hypercalcemia also increase sensitivity.

Stages and Symptoms

GI (Early): Anorexia, nausea, vomiting, abdominal pain.
Neurological/Visual: Fatigue, confusion, delirium, xanthopsia (yellow-green halos).
Cardiac (Late/Severe): ↑automaticity + ↓AV conduction → PVCs, bidirectional ventricular tachycardia, high-degree AV blocks.

Management

Stop digoxin and potassium-wasting diuretics.
Correct hypokalemia (unless high-degree AV block present).
Antiarrhythmics: Phenytoin or lidocaine (avoid Class IA agents and CCBs).
Antidote: Digoxin-specific antibody fragments (DigiFab) - for life-threatening arrhythmias, severe hyperkalemia, or massive overdose.

5. Antiarrhythmic Agents - Class I

Block voltage-gated Na⁺ channels during Phase 0 of the action potential.

Classification and Mechanisms

Class	Block Strength	Effect on APD/QT	Drugs
IA	Moderate	Prolongs (blocks Na⁺ + K⁺)	Quinidine, procainamide, disopyramide
IB	Weak	Shortens (binds inactivated channels)	Lidocaine, mexiletine
IC	Strong	No change (markedly slows Phase 0)	Flecainide, propafenone

Indications

Class IA: AF rhythm control, ventricular tachycardia.
Class IB: Acute ventricular arrhythmias (post-MI, digitalis-induced).
Class IC: SVT, AF without structural heart disease.

Side Effects

Class IA: Torsades de pointes (↑QT), drug-induced lupus (procainamide), cinchonism (quinidine).
Class IB: CNS toxicity - confusion, paresthesias, seizures, slurred speech.
Class IC: Highly proarrhythmic post-MI (CAST trial); metallic taste (propafenone).

6. Calcium Channel Blockers (CCBs)

Inhibit L-type Ca²⁺ channel influx in vascular smooth muscle and cardiac cells.

Classification and Mechanisms

Dihydropyridines (Vascular-selective): Amlodipine, nifedipine, felodipine.

Block vascular smooth muscle L-type channels → peripheral vasodilation; minimal cardiac effect.

Non-Dihydropyridines (Cardio-selective):

Verapamil (phenylalkylamine), diltiazem (benzothiazepine).
Block L-type channels in myocardium, SA node, AV node → negative inotropy, chronotropy, dromotropy.

Indications

Dihydropyridines: Hypertension, angina, Raynaud's phenomenon.
Non-Dihydropyridines: Rate control in AF/flutter, SVT prophylaxis, angina.

Side Effects

Dihydropyridines: Peripheral edema, reflex tachycardia, flushing, headache.
Non-Dihydropyridines: Bradycardia, AV block, constipation (verapamil), worsens HFrEF.

7. Nitrates

Prodrugs metabolized to release Nitric Oxide (NO).

Mechanisms and Features of Action

NO → stimulates soluble guanylyl cyclase → ↑cGMP → activates protein kinase G → dephosphorylation of myosin light chains → smooth muscle relaxation.

Therapeutic doses: Predominantly venous dilation → ↑venous capacitance → ↓preload → ↓myocardial O₂ demand.
High doses: Also arterial dilation → ↓afterload.
Nitrate tolerance: Continuous use depletes sulfhydryl groups. Prevent with a 10-12 hour nitrate-free interval daily.

Use

Acute and prophylactic angina.
Acute decompensated heart failure (↓preload).
Hypertensive emergencies (IV nitroglycerin).

Side Effects

Throbbing headache (meningeal artery dilation).
Reflex tachycardia, orthostatic hypotension, flushing.
Absolute contraindication: PDE-5 inhibitors (sildenafil) → life-threatening hypotension.

8. Lipid-Lowering Agents

Classification and Principles of Action

Class	Drugs	Primary Mechanism
Statins	Atorvastatin, rosuvastatin	Inhibit HMG-CoA reductase
Cholesterol absorption inhibitors	Ezetimibe	Block NPC1L1 transporter
PCSK9 inhibitors	Alirocumab, evolocumab	Prevent LDL receptor degradation
Fibrates	Fenofibrate, gemfibrozil	Activate PPARα → ↑lipoprotein lipase (↓TG)
Bile acid sequestrants	Cholestyramine, colesevelam	Bind bile acids in gut → ↑LDL receptor synthesis

Statins: Mechanism, Indications, Side Effects

Mechanism: Competitively inhibit HMG-CoA reductase → block HMG-CoA → mevalonate conversion (rate-limiting step) → ↓intracellular cholesterol → liver upregulates LDL receptors → ↓circulating LDL.

Indications: Hypercholesterolemia; primary and secondary prevention of MI and stroke.

Side Effects: Myalgia, myopathy, rare rhabdomyolysis (↑risk with fibrates or CYP3A4 inhibitors), elevated liver transaminases, slight ↑blood glucose. Contraindicated in pregnancy.

9. Diuretics: Classification and General Mechanisms

Diuretics increase urine output by inhibiting sodium and water reabsorption at specific nephron sites, reducing blood volume and pressure.

Classification by Nephron Site

Site	Drug Class
Proximal convoluted tubule (PCT)	Carbonic anhydrase inhibitors, osmotic diuretics
Thick ascending limb (Loop of Henle)	Loop diuretics
Distal convoluted tubule (DCT)	Thiazide and thiazide-like diuretics
Cortical collecting tubule	Potassium-sparing diuretics

10. Carbonic Anhydrase Inhibitors and Osmotic Diuretics

Carbonic Anhydrase Inhibitors (e.g., Acetazolamide)

Mechanism: Inhibits carbonic anhydrase in PCT → blocks H₂CO₃ → CO₂ + H₂O conversion → prevents NaHCO₃ reabsorption → alkaline diuresis + metabolic acidosis.

Uses: Glaucoma (↓aqueous humor), acute mountain sickness, urinary alkalinization.

Side Effects: Hyperchloremic metabolic acidosis, hypokalemia, calcium phosphate kidney stones, sulfonamide hypersensitivity.

Osmotic Diuretics (e.g., Mannitol)

Mechanism: Non-absorbable solute freely filtered at glomerulus → creates osmotic gradient in tubule → holds water in lumen. Initially extracts intracellular water → expands extracellular volume.

Uses: ↓Intracranial pressure (cerebral edema), ↓intraocular pressure.

Side Effects: Transient ECF expansion (can precipitate pulmonary edema/heart failure), dehydration, hypernatremia.

11. Loop Diuretics, Thiazides, and Thiazide-Like Diuretics

Loop Diuretics (e.g., Furosemide, Bumetanide, Torsemide)

Mechanism: Reversibly inhibit NKCC2 cotransporter in thick ascending limb → block 25% of filtered Na⁺ reabsorption → also disrupt lumen-positive potential → ↓Ca²⁺ and Mg²⁺ reabsorption.

Features: High-ceiling diuretics; effective even at low GFR.

Indications: Acute pulmonary edema, heart failure, hepatic cirrhosis, renal failure edema, severe hypercalcemia.

Side Effects: Hypokalemia, metabolic alkalosis, hypomagnesemia, hypocalcemia, hyperuricemia (gout), ototoxicity, sulfonamide allergy.

Thiazide and Thiazide-Like Diuretics (e.g., Hydrochlorothiazide, Chlorthalidone, Indapamide)

Mechanism: Inhibit NCC cotransporter in early DCT → block 5-10% Na⁺ reabsorption → ↑distal Na⁺ delivery → ↑Ca²⁺ reabsorption via basolateral Na⁺/Ca²⁺ exchanger.

Features: Lose efficacy at GFR <30 mL/min (except indapamide and metolazone).

Indications: Essential hypertension (first-line), mild heart failure, nephrogenic diabetes insipidus, calcium nephrolithiasis.

Side Effects: Hypokalemia, metabolic alkalosis, hyponatremia, hypercalcemia, hyperuricemia, hyperglycemia, hyperlipidemia.

12. Potassium-Sparing Diuretics

Classification and Mechanisms

Aldosterone Antagonists: Spironolactone, eplerenone.

Competitively block mineralocorticoid receptors in collecting duct principal cells → prevent aldosterone-driven ENaC and Na⁺/K⁺-ATPase upregulation → ↓Na⁺ reabsorption, ↓K⁺ secretion.
Spironolactone has anti-androgenic effects (steroid receptor cross-reactivity); eplerenone is more selective.

ENaC Blockers: Amiloride, triamterene.

Directly block epithelial sodium channels (ENaC) in collecting duct, independent of aldosterone → ↓electrochemical gradient driving K⁺ secretion.

Use

Combined with loop/thiazide diuretics to prevent hypokalemia.
Spironolactone: HFrEF (reduces mortality), primary hyperaldosteronism, liver cirrhosis with ascites.
Amiloride: Adjunct in hypertension, lithium-induced nephrogenic DI.

Side Effects

All: Hyperkalemia (major risk - dangerous with renal impairment or ACE inhibitors/ARBs).
Spironolactone: Gynecomastia, impotence, menstrual irregularities (anti-androgenic).
Triamterene: Kidney stones, megaloblastic anemia (folate antagonism).

13. ACE Inhibitors

Mechanism of Action

Inhibit angiotensin-converting enzyme (ACE):

↓Angiotensin II → vasodilation (↓afterload and preload) → ↓blood pressure.
↓Aldosterone → ↓Na⁺/water retention.
Bradykinin accumulates (ACE also degrades bradykinin) → additional vasodilation; causes dry cough and angioedema.
Dilate efferent arteriole → ↓intraglomerular pressure → renoprotection in diabetic/hypertensive nephropathy.

Drugs: Enalapril, lisinopril, ramipril, captopril.

Indications

Hypertension (first-line, especially with DM or CKD).
HFrEF (reduces mortality).
Post-MI (prevents ventricular remodeling).
Diabetic and proteinuric nephropathy.

Side Effects

Dry cough (bradykinin - most common reason for switching to ARB).
Angioedema (rare; bradykinin-mediated; absolute contraindication to re-use).
Hyperkalemia, first-dose hypotension.
AKI in bilateral renal artery stenosis.
Teratogenic - contraindicated in pregnancy.

14. AT₁-Receptor Blockers (ARBs)

Mechanism of Action

Selectively block AT₁ receptors → directly prevent angiotensin II effects (vasoconstriction, aldosterone release, sympathetic activation) → ↓blood pressure, ↓Na⁺ retention.

Key difference from ACEi: Do not inhibit ACE → no bradykinin accumulation → no dry cough. Angiotensin II may act on AT₂ receptors (vasodilation, anti-proliferative).

Drugs: Losartan, valsartan, candesartan, irbesartan.

Indications

Hypertension (preferred when ACEi cough occurs).
HFrEF, post-MI.
Diabetic nephropathy (T2DM - specific evidence for losartan, irbesartan).
Stroke prevention in hypertension with LVH (losartan).

Side Effects

Hyperkalemia, hypotension, AKI (same as ACEi).
No cough (main advantage over ACEi).
Angioedema (extremely rare).
Teratogenic - contraindicated in pregnancy.

15. Antiemetic Agents

Classification and Mechanisms

D₂ Receptor Antagonists: Metoclopramide, domperidone, prochlorperazine.

Block D₂ receptors in CTZ (area postrema). Metoclopramide also enhances gastric motility (prokinetic). Domperidone does not cross BBB → fewer extrapyramidal effects.

5-HT₃ Antagonists: Ondansetron, granisetron, tropisetron.

Block 5-HT₃ receptors on vagal afferents and in CTZ → highly effective for chemotherapy-induced nausea (CINV).

NK₁ Receptor Antagonists: Aprepitant, fosaprepitant.

Block substance P at NK₁ receptors → effective for delayed CINV (combined with 5-HT₃ antagonist + dexamethasone).

H₁ Antihistamines: Dimenhydrinate, meclizine, promethazine.

Block H₁ receptors in vestibular nuclei → motion sickness.

Anticholinergics: Scopolamine (transdermal) - block muscarinic receptors in vestibular system → motion sickness.

Corticosteroids: Dexamethasone - adjunct in CINV regimens.

Indications

Ondansetron: CINV, PONV.
Aprepitant: Delayed CINV.
Metoclopramide: Gastroparesis, GERD, postoperative nausea.
Dimenhydrinate/Scopolamine: Motion sickness, Meniere's disease.
Domperidone: Nausea in Parkinson's disease.

Side Effects

D₂ Antagonists: Extrapyramidal effects (dystonia, akathisia, tardive dyskinesia), hyperprolactinemia, sedation.
5-HT₃ Antagonists: Headache, constipation, QT prolongation.
NK₁ Antagonists: Fatigue, hiccups, CYP3A4 inhibition (drug interactions).
H₁ Antihistamines/Scopolamine: Sedation, dry mouth, blurred vision, urinary retention.

16. Drugs That Reduce Gastric Acidity

Classification and Mechanisms

Proton Pump Inhibitors (PPIs): Omeprazole, pantoprazole, lansoprazole, esomeprazole.

Prodrugs activated in acidic parietal cell canaliculi → irreversibly inhibit H⁺/K⁺-ATPase (proton pump) → most potent acid suppression. Take 30 minutes before meals.

H₂ Receptor Antagonists: Ranitidine, famotidine, cimetidine.

Competitively block H₂ receptors on parietal cells → ↓histamine-stimulated acid secretion. Tolerance develops with continuous use.

Antacids: Aluminum hydroxide, magnesium hydroxide, calcium carbonate.

Chemically neutralize secreted HCl. Rapid but short-lived relief. Al³⁺ → constipation; Mg²⁺ → diarrhea.

Mucosal Protectants:

Sucralfate: Polymerizes in acid → adheres to ulcer craters → physical protection.
Misoprostol (PGE₁ analogue): ↑mucus/bicarbonate secretion, ↓acid secretion → prevents NSAID-induced gastropathy.
Bismuth subcitrate: Coats ulcer craters, anti-H. pylori activity.

Indications

PPIs: GERD, PUD, H. pylori eradication, Zollinger-Ellison syndrome, NSAID ulcer prevention.
H₂RAs: Mild GERD, PUD, stress ulcer prophylaxis.
Antacids: Symptomatic heartburn relief.
Misoprostol: NSAID-induced ulcer prevention (high-risk patients).

Side Effects

PPIs (long-term): Hypomagnesemia, C. difficile infection risk, osteoporosis/fractures, B₁₂ malabsorption, rebound acid hypersecretion on discontinuation.
H₂RAs: Cimetidine - gynecomastia, impotence, CYP450 inhibition (multiple drug interactions).
Antacids: Constipation (Al), diarrhea (Mg), milk-alkali syndrome (Ca), impaired absorption of other drugs.
Misoprostol: Diarrhea, abdominal cramps. Contraindicated in pregnancy (uterotonic).

17. Laxatives

Classification and Mechanisms

Bulk-Forming: Psyllium, methylcellulose, bran.

Absorb water → swell → ↑stool bulk → stimulate peristalsis via stretch receptors. Safest long-term; must take with adequate water.

Osmotic: Lactulose, PEG (macrogol), magnesium hydroxide, sorbitol.

Non-absorbable solutes → retain water in lumen → ↑luminal volume → stimulate motility. Lactulose also acidifies colon → traps NH₄⁺ (used in hepatic encephalopathy).

Stimulant (Contact): Bisacodyl, senna, sodium picosulfate, castor oil.

Stimulate myenteric plexus → ↑peristalsis; inhibit colonic water/electrolyte absorption.

Stool Softeners: Docusate sodium.

Anionic surfactant → reduces surface tension → allows water/lipid penetration of stool.

Lubricants: Liquid paraffin (mineral oil).

Coats feces → prevents water reabsorption → lubricates passage.

Use

Bulk-forming: Chronic constipation, IBS-C, pregnancy.
Lactulose: Constipation, hepatic encephalopathy.
PEG: Chronic constipation, bowel prep for colonoscopy.
Stimulant: Short-term acute constipation, procedure bowel prep.
Docusate: Post-surgical/post-MI (avoid straining).

Side Effects

Bulk-forming: Bloating, flatulence, obstruction if taken without water.
Lactulose: Flatulence, cramping, diarrhea.
Stimulant (chronic): Hypokalemia, melanosis coli (anthraquinones), laxative dependence.
Liquid paraffin: Lipid pneumonia (aspiration), fat-soluble vitamin malabsorption.

18. Drugs Affecting the Uterus

Classification and Mechanisms

Uterotonics:

Oxytocin/Carbetocin: Bind Gq-coupled oxytocin receptors → ↑IP₃ → ↑intracellular Ca²⁺ → rhythmic myometrial contractions. Short half-life (~5 min); carbetocin lasts ~1 hour.

Ergot Alkaloids (Ergometrine, Methylergometrine): Partial agonists at 5-HT₂, dopamine, and α-adrenergic receptors → sustained tetanic contractions + vasoconstriction. Not for labor induction.

Prostaglandins (Dinoprostone-PGE₂, Carboprost-PGF₂α, Misoprostol-PGE₁): Bind EP/FP receptors → ↑Ca²⁺ → contractions. PGE₂ also causes cervical ripening.

Tocolytics (Uterine Relaxants):

β₂-Agonists (Ritodrine, Terbutaline): Stimulate β₂ receptors → ↑cAMP → ↑PKA → phosphorylates and inactivates MLCK → relaxation.

Nifedipine (CCB): Blocks L-type Ca²⁺ channels in myometrium → ↓contractions. Preferred tocolytic.

Atosiban: Competitive oxytocin receptor antagonist → directly inhibits contractions.

Magnesium Sulfate: Competes with Ca²⁺ at myometrial membrane + fetal neuroprotection.

Indications

Oxytocin: Labor induction/augmentation; postpartum hemorrhage (PPH) first-line.
Ergometrine: PPH treatment (second-line).
Misoprostol/Dinoprostone: Cervical ripening, labor induction, medical abortion, PPH.
Tocolytics (nifedipine, atosiban): Preterm labor - delay delivery to allow fetal lung maturation with corticosteroids.

Side Effects

Oxytocin: Water retention/hyponatremia, hypotension, uterine hyperstimulation, fetal distress, uterine rupture.
Ergometrine: Hypertension (contraindicated in pre-eclampsia), coronary vasospasm (contraindicated in IHD), nausea/vomiting.
Carboprost: Bronchospasm (contraindicated in asthma), diarrhea, fever.
β₂-Agonist tocolytics: Tachycardia, hyperglycemia, hypokalemia, pulmonary edema (IV use).
MgSO₄: Flushing, respiratory depression, cardiac arrest at toxic levels. Antidote: calcium gluconate.

19. Antiplatelet Agents

Classification and Mechanisms

COX Inhibitors: Aspirin.

Irreversibly acetylates COX-1 → blocks TXA₂ synthesis (platelet activator/vasoconstrictor) for platelet lifetime (7-10 days). Low dose (75-150 mg) preferentially inhibits platelet TXA₂ while sparing endothelial PGI₂.

P2Y₁₂ ADP Receptor Antagonists:

Thienopyridines (prodrugs): Clopidogrel, prasugrel, ticlopidine → irreversibly block P2Y₁₂ after CYP activation.
Direct-acting: Ticagrelor (reversible, oral), cangrelor (reversible, IV) → direct P2Y₁₂ block, no CYP dependence.

GP IIb/IIIa Receptor Antagonists: Abciximab, eptifibatide, tirofiban (IV only).

Block the final common pathway of platelet aggregation (fibrinogen cannot cross-link platelets).

PDE Inhibitors: Dipyridamole, cilostazol.

↑cAMP → suppress platelet activation. Dipyridamole also inhibits adenosine reuptake.

Indications

Aspirin: ACS, post-MI, ischemic stroke/TIA prevention, post-PCI.
Clopidogrel/Ticagrelor/Prasugrel: ACS (DAPT with aspirin), post-coronary stenting, PAD.
GP IIb/IIIa Antagonists: High-risk PCI.
Dipyridamole + Aspirin: Secondary stroke/TIA prevention.
Cilostazol: Intermittent claudication.

Side Effects

Aspirin: GI bleeding, peptic ulceration, hypersensitivity (aspirin-exacerbated respiratory disease), Reye's syndrome (children).
Clopidogrel: Bleeding; variable response (CYP2C19 polymorphism). TTP with ticlopidine.
Ticagrelor: Bleeding, dyspnea (adenosine-mediated), bradycardia.
GP IIb/IIIa Antagonists: Bleeding, thrombocytopenia.
Cilostazol: Headache, palpitations. Contraindicated in heart failure.

20. Heparin: Origin, Structure, Mechanisms, Indications, Side Effects. Direct Thrombin and Xa Inhibitors

Heparin

Origin/Structure: Naturally occurring glycosaminoglycan from porcine intestinal mucosa or bovine lung. Sulfated polysaccharide (MW 3,000-30,000 Da, mean ~15,000 Da) with a key pentasaccharide sequence that binds antithrombin III (AT-III).

Mechanism: Binds AT-III → conformational change → AT-III inhibitory activity ↑1,000-10,000x → irreversibly inhibits thrombin (IIa), Factor Xa, IXa, XIa, XIIa. UFH inhibits IIa and Xa equally.

Features:

IV infusion or subcutaneous. Not orally bioavailable.
Cannot cross placenta → safe in pregnancy.
Monitored by aPTT (target 1.5-2.5x control).
Antidote: Protamine sulfate.

Indications: DVT/PE treatment and prevention, ACS, cardiac surgery, hemodialysis, perioperative bridging.

Side Effects:

Bleeding (primary risk).
HIT Type II (immune-mediated: IgG antibodies vs. heparin-PF4 complexes → paradoxical thrombosis + thrombocytopenia; stop heparin immediately → switch to direct thrombin inhibitor, e.g., argatroban).
Osteoporosis (long-term), elevated liver transaminases.

Direct Thrombin Inhibitors (DTIs)

Parenteral: Argatroban (hepatic clearance - use in HIT/renal failure), bivalirudin (PCI).
Oral: Dabigatran etexilate (renal clearance). Antidote: Idarucizumab.
Mechanism: Directly bind thrombin active site, AT-III-independent. Inhibit both free and clot-bound thrombin.

Direct Factor Xa Inhibitors

Oral: Rivaroxaban, apixaban, edoxaban.
Parenteral: Fondaparinux (synthetic pentasaccharide; AT-III-dependent, anti-Xa only).
Mechanism: Directly inhibit Factor Xa → block prothrombin → thrombin conversion.
Antidote: Andexanet alfa (for rivaroxaban/apixaban). No specific antidote for fondaparinux.
Indications: AF stroke prevention, DVT/PE treatment, post-orthopedic thromboprophylaxis.

21. Low Molecular Weight Heparins (LMWHs)

Derived from UFH by depolymerization → MW 1,000-10,000 Da (mean ~5,000 Da).

Mechanisms and Features

Mechanism: Act via AT-III. Shorter chains → preferential anti-Xa over anti-IIa activity (2:1 to 4:1) (too short to bridge AT-III and thrombin simultaneously).

Advantages over UFH:

Predictable pharmacokinetics; >90% subcutaneous bioavailability.
Longer half-life (4-6 h) → once/twice daily dosing.
No routine aPTT monitoring (anti-Xa levels in special populations).
Lower HIT Type II risk.
Partial reversal with protamine (neutralizes anti-IIa, not anti-Xa).

Drugs: Enoxaparin, dalteparin, nadroparin, tinzaparin.

Indications

DVT/PE prevention and treatment.
ACS (unstable angina, NSTEMI).
Anticoagulation in pregnancy (drug of choice with UFH).
Perioperative bridging anticoagulation.

Side Effects

Bleeding (less than UFH at equivalent doses).
HIT Type II (less frequent than UFH but possible).
Injection-site bruising/hematoma.
Accumulation in renal failure (renally cleared) → dose reduce or switch to UFH if CrCl <30 mL/min.

22. Warfarin

Oral anticoagulant; vitamin K antagonist (coumarin class).

Mechanisms and Features

Mechanism: Inhibits VKORC1 → blocks recycling of vitamin K epoxide → depletes active vitamin K hydroquinone → impairs γ-carboxylation of clotting factors II, VII, IX, X and anticoagulant Protein C and Protein S.

Features:

Delayed onset: 2-3 days (existing factors consumed first; Factor VII falls first → early INR rise).
Full effect: 5-7 days.
Monitored by INR (target 2.0-3.0 for most; 2.5-3.5 for mechanical valves).
99% protein-bound → extensive drug interactions.
Teratogenic - contraindicated in pregnancy (1st and 3rd trimesters).
Antidote: Vitamin K₁ (12-24 h reversal); urgent: 4-factor PCC or FFP.

Drug interactions: ↑effect: CYP2C9 inhibitors (amiodarone, fluconazole, metronidazole), aspirin, broad-spectrum antibiotics. ↓effect: CYP2C9 inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort), dietary vitamin K.

Indications

AF stroke prevention (valvular AF or DOAC-contraindicated).
DVT/PE treatment and secondary prevention.
Mechanical prosthetic heart valves (only anticoagulant approved).
Antiphospholipid syndrome.

Side Effects

Bleeding (intracranial hemorrhage most feared).
Warfarin skin necrosis (days 3-5; Protein C/S deficiency → transient hypercoagulable state).
Teratogenicity: Warfarin embryopathy (weeks 6-12); fetal hemorrhage (3rd trimester).
Purple toe syndrome, extensive drug/food interactions.

23. Thrombolytic Drugs

Mechanisms of Action

Activate plasminogen → plasmin → cleaves fibrin → clot dissolution. Also degrade fibrinogen, Factor V, Factor VIII (systemic lytic state).

Drug	Selectivity	Features
Streptokinase	Non-selective	Bacterial; forms 1:1 complex with plasminogen; antigenic; cannot re-use
Alteplase (rt-PA)	Fibrin-selective	Recombinant tPA; activates fibrin-bound plasminogen; short t½ (5 min), continuous infusion
Tenecteplase	High fibrin-selective	Single IV bolus; resistant to PAI-1
Reteplase	Moderate selective	Double bolus; longer t½ than alteplase
Urokinase	Non-selective	Human serine protease; direct plasminogen activator; catheter use

Therapeutic Use

STEMI: When PCI not available within 120 min (alteplase, tenecteplase preferred).
Massive PE with hemodynamic instability.
Acute ischemic stroke: Alteplase/tenecteplase within 4.5 hours of onset.
Massive DVT with limb-threatening ischemia (catheter-directed).

Adverse Effects

Bleeding (major complication) - intracranial hemorrhage (~0.9-1% in stroke).
Streptokinase: Allergic/anaphylactic reactions, hypotension (bradykinin), resistance on re-exposure.
Reperfusion arrhythmias (post-coronary thrombolysis - usually transient).

Absolute contraindications: Prior intracranial hemorrhage, active internal bleeding, recent intracranial surgery/trauma, intracranial neoplasm, severe uncontrolled hypertension.

24. Fibrinolytic Agents

Classification

Generation	Drugs	Selectivity
1st (non-selective)	Streptokinase, urokinase	Systemic plasminogen activation; high bleeding risk
2nd (fibrin-selective)	Alteplase (rt-PA)	Preferential fibrin-bound plasminogen activation
3rd (enhanced)	Tenecteplase, reteplase	Greater fibrin selectivity; PAI-1 resistance; bolus dosing

Mechanisms

All produce plasmin from plasminogen → cleaves fibrin → produces fibrin degradation products (FDPs) and D-dimers (clinical markers of fibrinolysis).

Clinical Use

Same as thrombolytics (STEMI, massive PE, acute ischemic stroke).
Catheter-Directed Thrombolysis (CDT): Low-dose fibrinolytic infused directly into thrombus via catheter → higher local effect, lower systemic dose → ↓bleeding risk. Used for sub-massive PE, iliofemoral DVT, peripheral arterial occlusion.

Side Effects

Same as thrombolytics. Key differentiator: streptokinase is antigenic and cannot be re-used within 6-12 months.

25. Iron Drugs

Metabolism of Iron

Reduction: Dietary Fe³⁺ → Fe²⁺ by duodenal cytochrome B (DcytB).
Intestinal absorption: Fe²⁺ enters enterocyte via DMT-1 (duodenum/upper jejunum).
Export: Fe²⁺ exported via ferroportin → oxidized to Fe³⁺ by hephaestin → binds transferrin for plasma transport.
Cellular uptake: Transferrin-Fe³⁺ → binds TfR1 receptors → endocytosis → Fe³⁺ reduced to Fe²⁺ by STEAP3 → released to cytoplasm.
Storage: Ferritin (soluble, short-term) and hemosiderin (insoluble, long-term) in liver, spleen, bone marrow.
Regulation: Hepcidin (liver) binds ferroportin → internalization/degradation → blocks iron export. Inflammation ↑hepcidin → anemia of chronic disease.
Excretion: No regulated excretion (lost via epithelial shedding, menstruation).

Classification

Oral (Fe²⁺ salts): Ferrous sulfate (first-line), ferrous gluconate, ferrous fumarate.
Parenteral: Iron sucrose, ferric carboxymaltose, iron dextran, ferumoxytol.

Mechanisms and Clinical Use

Replenish iron stores → restore Hb synthesis, myoglobin, cytochromes.
Oral iron: Take fasting with vitamin C (enhances absorption). Reticulocyte ↑in 3-5 days; Hb rises at 1-2 weeks; continue 3-6 months after normalization to replenish stores.
Parenteral iron: Used when oral not tolerated/absorbed; IBD, CKD on dialysis, heart failure, pre-operative anemia.

Side Effects

Oral: Nausea, epigastric discomfort, constipation, black stools (harmless). GI intolerance → poor compliance.

Parenteral: Anaphylaxis/hypersensitivity (especially high-MW iron dextran), hypotension, arthralgia, iron overload.

Acute overdose (children): GI toxicity → apparent recovery → metabolic acidosis, hepatotoxicity, shock. Treatment: gastric lavage + deferoxamine (chelating agent).

26. Cyanocobalamin (Vitamin B₁₂)

Oral Metabolism

Stomach: Pepsin/acid releases B₁₂ from food → B₁₂ binds R-protein (haptocorrin); parietal cells secrete Intrinsic Factor (IF).
Duodenum: Pancreatic proteases degrade R-protein → free B₁₂ binds IF → IF-B₁₂ complex formed.
Terminal ileum: IF-B₁₂ binds cubilin receptors → endocytosis → B₁₂ released → enters portal circulation bound to transcobalamin II.
Storage: Liver stores 2,000-5,000 μg (3-5 years supply).

Causes of deficiency: Pernicious anemia (autoimmune destruction of parietal cells → no IF), gastrectomy, atrophic gastritis, terminal ileum disease/resection (Crohn's), strict veganism, long-term metformin/PPI use.

Passive absorption: 1-2% absorbed by passive diffusion throughout small intestine (basis for high-dose oral therapy: 1,000-2,000 μg/day even in pernicious anemia).

Clinical Uses

Biochemical roles:

Methylcobalamin: Cofactor for methionine synthase → homocysteine → methionine. Deficiency → "folate trap" → ↓THF → impaired DNA synthesis → megaloblastic anemia.
Adenosylcobalamin: Cofactor for methylmalonyl-CoA mutase → methylmalonyl-CoA → succinyl-CoA. Deficiency → MMA accumulates → subacute combined degeneration of the spinal cord (posterior + lateral column degeneration).

Indications:

Megaloblastic (macrocytic) anemia due to B₁₂ deficiency.
Pernicious anemia (IM hydroxocobalamin or high-dose oral).
Subacute combined degeneration of spinal cord.
Prevention in at-risk groups (vegans, post-gastrectomy, elderly, long-term metformin/PPI users).

Formulations: Cyanocobalamin (synthetic, stable), hydroxocobalamin (longer-acting; also antidote for cyanide poisoning), methylcobalamin, adenosylcobalamin.

Side Effects

Generally extremely safe (water-soluble; excess excreted).

Rare: mild diarrhea, skin rash.
IM injection: local pain, reactions.
Hypokalemia (during initial treatment of severe megaloblastic anemia - rapid erythropoiesis consumes K⁺).

27. Drugs for Diabetes Mellitus Type 1: Insulin and Insulin Analogues

Mechanism of Action

Insulin binds transmembrane tyrosine kinase insulin receptor → IRS-1/PI3K/Akt cascade:

↑GLUT-4 translocation (↑glucose uptake in muscle/adipose).
↑Glycogen synthesis (liver/muscle).
↑Lipogenesis, ↓lipolysis.
↑Protein synthesis.
↓Gluconeogenesis, glycogenolysis, ketogenesis.

Classification by Duration

Type	Drugs	Onset	Peak	Duration
Rapid-Acting	Lispro, aspart, glulisine	5-15 min	30-90 min	3-5 h
Short-Acting (Regular)	Actrapid/neutral insulin	30-60 min	2-3 h	5-8 h
Intermediate	NPH (Isophane)	1-2 h	4-8 h	12-18 h
Long-Acting	Glargine, detemir	1-2 h	Peakless	20-24 h
Ultra-Long	Degludec	30-90 min	Peakless	>42 h

Rapid-acting analogues: Engineered to exist as monomers at injection site → faster absorption. Lispro: B28-B29 reversal; aspart: B28 Pro→Asp.

Long-acting analogues: Glargine: A21 mutation + 2 Arg additions → microprecipitates at physiological pH → slow release. Detemir: fatty acid acylation → albumin binding → buffered release.

Insulin Regimens in T1DM

Basal-Bolus (Gold Standard): Long-acting (glargine/detemir) once daily + rapid-acting (lispro/aspart) before each meal.
CSII (Insulin Pump): Continuous subcutaneous rapid-acting insulin; programmable basal + bolus doses.

Side Effects

Hypoglycemia (primary risk): Adrenergic symptoms (sweating, tremor, palpitations) → neuroglycopenic symptoms (confusion, seizures, coma).
Weight gain.
Lipohypertrophy at injection sites (rotate sites).
Hypokalemia (K⁺ driven into cells).
Edema at treatment initiation.

28. Drugs for Diabetes Mellitus Type 2

T2DM: Peripheral insulin resistance + progressive beta-cell dysfunction.

Classification and Mechanisms

Biguanides - Metformin (First-Line):

Activates AMPK via ↑AMP:ATP ratio (inhibits mitochondrial Complex I) → ↓hepatic gluconeogenesis (primary effect) + ↑peripheral insulin sensitivity.
No hypoglycemia; weight-neutral to mildly reducing. ↓Cardiovascular events.
Adverse effects: GI (nausea, diarrhea - take with food), lactic acidosis (rare; hold before contrast media), B₁₂ malabsorption. Contraindicated if eGFR <30.

Sulfonylureas (Glibenclamide, Gliclazide, Glimepiride, Glipizide):

Close K_ATP channels on beta-cells → depolarization → ↑Ca²⁺ → insulin secretion (glucose-independent).
Adverse effects: Hypoglycemia (major, especially glibenclamide in elderly/renal impairment), weight gain.

Meglitinides/Glinides (Repaglinide, Nateglinide):

Same K_ATP mechanism; rapid onset and short duration → prandial insulin secretion (take with meals only).
Adverse effects: Hypoglycemia (less than sulfonylureas), weight gain.

Thiazolidinediones/Glitazones (Pioglitazone, Rosiglitazone):

Activate PPARγ → ↑GLUT-4 expression, ↑adiponectin → ↑peripheral insulin sensitivity. Slow onset (weeks).
Adverse effects: Fluid retention/edema (contraindicated in heart failure), weight gain, bone fractures (women), rosiglitazone → ↑MI risk, pioglitazone → possible bladder cancer.

DPP-4 Inhibitors/Gliptins (Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin):

Inhibit DPP-4 → prevent incretin (GLP-1, GIP) degradation → ↑GLP-1/GIP → glucose-dependent insulin secretion + ↓glucagon. Minimal hypoglycemia risk; weight-neutral.
Adverse effects: Nasopharyngitis, UTIs. Rare: acute pancreatitis. Saxagliptin/alogliptin → ↑heart failure hospitalization.

GLP-1 Receptor Agonists (Liraglutide, Semaglutide, Dulaglutide, Exenatide):

Bind GLP-1 receptors → glucose-dependent insulin secretion + ↓glucagon + ↓gastric emptying + central appetite suppression → significant weight loss (5-10%). ↓MACE in established CVD (LEADER, SUSTAIN-6 trials). SC injection (except oral semaglutide).
Adverse effects: Nausea, vomiting, diarrhea (most common; dose-dependent). Rare: pancreatitis. Contraindicated in MEN2/medullary thyroid carcinoma (thyroid C-cell risk in rodents). Gallstones.

SGLT-2 Inhibitors/Gliflozins (Empagliflozin, Dapagliflozin, Canagliflozin):

Inhibit SGLT-2 in PCT → block ~90% of filtered glucose reabsorption → glucosuria (60-100g/day) → ↓blood glucose (insulin-independent). Also cause natriuresis → ↓BP, ↓preload. Profound ↓heart failure hospitalization + renoprotection (EMPA-REG, CANVAS, DECLARE trials). Weight loss.
Adverse effects: Genital mycotic infections, UTIs (glucosuria). Euglycemic DKA (rare but serious). Fournier's gangrene (rare). Polyuria, volume depletion. Canagliflozin: ↑lower limb amputations and bone fractures (FDA black box warning).

Alpha-Glucosidase Inhibitors (Acarbose, Miglitol):

Inhibit intestinal brush-border alpha-glucosidases → delay carbohydrate digestion/absorption → ↓postprandial glucose. No systemic absorption; no hypoglycemia alone; modest efficacy.
Adverse effects: Flatulence, bloating, diarrhea (fermentation of undigested carbohydrates) - major limitation.

All 28 questions are now written in a concise, exam-oriented format - essential mechanisms, key drugs, core indications, and must-know side effects only. No filler explanations.

Analyse all 1 to 28 questions, write the chapter name of pharmacology the belongs to.

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

This is a shared conversation. Sign in to Orris to start your own chat.